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1. ATHEROSCLEROSIS AND LIPOPROTEIN METABOLISM 
Cardiovascular disease (CVD) is the main cause of death in worldwide, 
every day, coronary disease, particularly heart attacks and stroke, kills 4500 
people in Europe and more than 17 million people in the world and it is 
attended by 2030 more than 23 million people will die annually from CVD 
[1].Atherosclerosis is a pathological condition characterized by the 
development and progression of plaque within arteries. It is described as 
inflammatory disease with lesions involving both lipid and cellular 
accumulation within the vessel wall and reactive intimal thickening of the 
artery. The onset of disease begins early, often in the childhood, and it is 
characterized by development of fatty streak followed by lipid deposition 
and accumulation of both extracellular matrix and intimal smooth muscle 
cells. Once the characteristic plaque has formed, it may remain 
asymptomatic for many years. However, as the disease progress, ischemia 
can appear with progressive occlusion of the vessel, or the plaque can 
suddenly rupture, resulting in thrombus formation. Rupture of a plaque 
frequently leads to one of the acute coronary syndromes (ACS), which 
include sudden death, acute myocardial infarction, or unstable angina. 
There are numerous known risk factors involved in development of 
atherosclerosis, among these, elevated plasma concentration of 
cholesterol, in particular the low-density lipoprotein (LDL) fraction, 
hypertension, diabetes mellitus, smoking and genetic predisposition are the 
most known and studied [2]. 
Total and LDL cholesterol impact on coronary disease is well established 
and the cardiovascular risk in linearly correlated to increasing plasma LDL 
levels. 
On the contrary, cholesterol levels associated to high-density lipoprotein 
(HLD) is inversely correlated to cardiovascular disease. 
Among the other lipid parameters, hypertriglyceridemia associated to higher 
levels of very-low-density lipoprotein (VLDL) and chylomicrons (CM) 
appears less atherogenic than hypercholesterolemia. Usually, elevated 
triglyceride levels are associated with lower HDL levels and it is hard to 
understand which risk factor has high contribution in developing 
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cardiovascular disease. Lipid are particularly and marked involved in the 
plaque developing and regression and consequently in the manifestation of 
cardiovascular disease [3]. 
 
1.1 LIPOPROTEIN CHARACHTERISTIC AND METABOLISM 
Levels of cholesterol and related lipids circulating in plasma are important 
predictive factors utilized clinically to estimate risk of a cardiovascular 
event. 
In circulation, cholesterol, requires a transport vesicle because, being a 
lipid, it need to be shielded from the aqueous nature of plasma. Complex, 
micelle-like amalgamations of various proteins and lipids accomplish 
cholesterol transport through the vascular system. These particles, called 
lipoproteins, are heterogeneous in size, shape, composition and function. 
Plasma lipoprotein are spherical particles containing a core that consist of 
nonpolar lipid, mostly triglyceride (TG) and cholesteryl ester (CE), 
surrounded by a surface coat consisting of proteins (apolipoproteins), and 
more polar lipids, phospholipids (PL) and unesterified (free) cholesterol 
(FC).  Lipoproteins are classified by their density and electrophoretic 
mobility into four major groups: chylomicrons, very-low-density (preβ) 
lipoproteins (VLDL), low-density (β) lipoproteins (LDL) and high-density (α) 
lipoprotein (HDL). After electrophoresis, chylomicrons remain at origin, and 
VLDL, LDL, and HDL migrate in the same position as preβ-, β- and α 
globulins, respectively. The main characteristic of these four classes are 
resumed in table 1 [4]. 
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 Chylomicrons VLDL LDL HDL 
Hydrated density 
range (g/ml) 
< 0.95 0.95-1.006 1.019-
1.063 
1.063-1.21 
Electrophoretic 
migration 
origin pre-β β α 
Average 
composition % 
    
Cholesterol 3 22 50 20 
Triglyceride 90 55 5 5 
Phospholipid 6 15 25 25 
Protein 1 8 20 50 
Major 
apolipoprtoteins 
apoB-48, apoA-I, 
apoA-IV, apoE 
apoB-100 
apoC-I, apoC-
II, apoC-III, 
apo-E 
apoB-100 apoA-I, apoA-
II 
apoC-I, apoC-
II, apoC-III, 
apo-E 
Origin Intestine Liver VLDL Liver, Intestine 
 
Table 1Classification and property of the major human plasma lipoprotein [4] 
 
Lipoproteins hydrated density is related to their chemical composition and 
the relative content of lipid and apolipoprotein. Chylomicrons (<0.95% g/ml) 
are 99% lipid, most of it TG;VLDL (0.95 to 1.006 g/ml) are about 90% lipid, 
the majority of it TG with smaller amount of cholesterol; LDL (1.019 to 1.063 
g/ml) are the major carriers of cholesterol in plasma and CE and FC 
represent 50% of their weight; HDL (1.063 to 1.21 g/ml) involve about the 
same equal amounts of apolipoprotein and lipid, principally PL and 
cholesterol [4]. 
Beside the main function to transport lipid in plasma, apolipoproteins have 
other generic functions, among these they are able to release lipoproteins 
from cells, facilitate the cellular uptake of intact lipoproteins or selective 
uptake of their lipids and regulate other aspects of lipoprotein metabolism 
such as intravascular remodeling and lipid transfer. The major lipoproteins 
have a variety of apolipoproteins associated with them; different 
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apolipoproteins have one or more specific functions as described in table 
n.2 [4]. 
Apolipoprotein Molecular 
weight 
Chromosoma
l location 
Function 
ApoA-I 29.016 11q23 Cofactor LCAT, facilitates both the 
transfer to cell cholesterol by 
ABCA1 to nascent HDL and the 
delivery of CE and FC on HDL to 
liver through SR-BI 
ApoA-II 17.414 1q21-23 Inhibit TG hydrolysis by HL and 
VLDL 
ApoA-IV 44.465 11q23 Activates LCAT, promotes 
chylomicron formation 
ApoA-V 39.000 11q23 Stimulates proteoglycan-bound 
LPL 
ApoB-100 512.723 2p24-p23 Secretion on VLDL from liver; 
binding ligand to LDLR 
ApoB-48 240.800 2p24-p23 Secretion of chylomicron from 
intestine 
ApoC-I 6.630 19q13.2 Inhibits apoE binding to LDLR; 
stimulates LCAT; inhibits CETP 
and SR-BI 
ApoC-II 8.900 19q13.2 Cofactor LPL 
ApoC-III 8.800 11q23.3 Inhibits LPL, binding apoE to 
LDLR 
ApoC-IV 11.000 19q13.2 Regulates TG metabolism 
ApoD 19.000 3q26.2 Promotes reverse cholesterol 
transport 
ApoE 34.145 19q13.2 Binding ligand for LRP on 
chylomicrons remanants and for 
LDLR on VLDL and HDL 
ApoF 29.000 12q13.3 Inhibitor of CETP 
ApoH 54.000 17q23 Activates LPL 
ApoJ 70.000 8p21-p12 Binding of hydrophobic molecules 
ApoL 42.000 22q13.1 Make only in pancreas, affect TG 
and glucose metabolism 
ApoM 25.000 6p21.33 Binding of small hydrophobic 
molecules 
 
Table n. 2 Description of characteristics and functionality of the major human 
apolipoprotein. LCAT lecithin:cholesterol acyltransferase, ABCA1 ATP-binding 
cassette A1, SR-BI scavenger receptor class B type I, LPL lipoprotein lipase, 
LDLR LDL receptor, CETP cholesteryl ester transfer protein, LRP LDL receptor-
related protein [4]. 
 
Usually,lipoprotein metabolism is described as consisting of three 
pathways: the exogenous pathway, the endogenous pathway and the 
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pathway of the reverse cholesterol transport. The exogenous pathway 
involves transport of lipid deriving form diet from the intestine to liver; the 
endogenous pathway involves transport of lipids synthesized in the liver to 
peripheral tissues. The two pathways meet at the step of hydrolysis by 
lipoprotein lipase (LPL) in the periphery and by hepatic triglyceride lipase 
(HTGL) in the liver. Reverse cholesterol transport is the pathway in which 
cholesterol is removed from peripheral tissues and is carried to the liver [5]. 
Availability of triglycerides determines the state of lipid transport system. 
Fatty acids are provided as components of triglyceride in the diet: in the fed 
state they are primarily sent to the adipose tissue for storage, but in the 
post-absorptive and fasting state, free fatty acids are provided from storage 
depots by lipolysis. Muscle and liver capture free fatty acids from lipolysis 
and depending on cell energy status they are either oxidized to yield energy 
or re-esterified to form TG [5]. 
In the exogenous pathway intestine absorbs dietary lipids and in the 
enterocyte cellslipidsare assembled with apoB -48, apoA-I e apoA-IV into 
chylomicrons. The microsomal triglyceride transfer protein (MTTP) is the 
key protein in chylomicrons package, MTTP function is to transfer TG into 
apoB-48. Chylomicrons, secreted via the lymphatic system, enter the vena 
cava and circulate until they interact with lipoprotein lipase (LPL) that 
hydrolyze their triglyceride with glycerol and fatty acids formation.  ApoC-II 
and apoA-V are cofactors for LPL activation, on the opposite,apoC-III has 
inhibitory proprieties. Aftertriglyceride hydrolysis, chylomicrons has smaller 
dimension and they are called “remnants”. The remnants are also 
characterized by altered apoE conformation that is necessary for binding to 
liver receptor in which remnants are eliminated. There are three different 
apoE isoforms: apoE-2, apoE-3 e apoE-4, (single aminoacid substitution in 
regions 112 and 158) with three different homozygous (E2/2, E3/3 e E4/4) 
and heterozygous (E2/3, E2/4, E3/4) phenotypes. ApoE2 has low affinity to 
hepatic receptor and it is not able to mediate remnants internalization [6]. 
In the liver cells (hepatocytes) the MTTP package TG with apoB-100, apoA-
V, apoC and apoE to synthetize VLDL particles. In plasma VLDL acquire 
other molecules of apoC and apoE from HDL. In the same way of 
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chylomicron metabolism, LPL hydrolyze TG in VLDL with VLDL remnants 
formation called IDL. 
IDL are transformed to LDL by hepatic lipase (HL) that hydrolyze TG and 
release apoC and apoE. LDL are characterized byenrichment in esterified 
cholesterol and contain only apoB-100 as protein. In healthy subjects 70% 
of total plasma cholesterol is consisted to LDL, large part of LDL are 
removed by liver through interaction with LDL receptor (LDLR), another 
small part is removed in the peripheral cells through interaction with LDLR 
or scavenger receptors. apoB-100 is the interact with LDLR that is 
expressed in all cells; after binding, LDL are internalized through 
endocytosis pathway and localize into lysosomes in which the esterified 
cholesterol has been hydrolyzed. The unesterified cholesterol become 
available for different physiological functions such as cellular membrane 
building, synthesis of steroid hormones, and if is needed, esterified a 
second time by ACAT and stored as cholesteryl ester into cell.LDLR 
expression is regulated by cholesterol content into cell, but on the contrary, 
scavenger receptor expression is not regulated.The LDL are sensitive to 
lipolytic hepatic lipase action; thus form small dense LDL characterized by a 
low ratio lipid/protein. Small and dense LDL are more atherogenic than 
large and low-dense LDL. The LDL become more atherogenic even when 
they are modified from oxidative processes in lipid and proteinform that 
facilitate interaction with receptors scavengers. A slowed down catabolism 
of LDL prolongs the half-life and promotes the oxidation, with a resulting 
increase in the deposition of cholesterol in the macrophages of the arterial 
wall, transformation into foam cells, formation and progress of the plaque 
[6].The cholesterol removal from arterial wall is mediated by HDL through 
the reverse cholesterol transport, an atheroprotective process that will be 
discussed later.Through RCT, cholesterol returns to liver in which it is 
eliminated through biliary excretion. Transporters ABCG5 and ABCG8 are 
expressed in liver and intestine and are involved in excretion of cholesterol. 
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Fig. 1.Schematic drawing of cholesterol metabolism. In intestine fats from diet are 
hydrolyzed and the reconstituted triglycerides are packed into chylomicrons with 
apoB48 and cholesteryl ester by MTTP.Cholesterol in the intestinal lumen enter 
enterocytes via the Niemann-Pick C1-like 1 (NPC1L1) transporter. Some sterols 
are resecreted by heterodimeric ATP-binding cassette transporter G5/G8 
(ABCG5/G8)and other are packed into chylomicrons. Chylomicrons also present 
other apoliporoteins (APOA5, APOC2 and APOC3) and are secreted via the 
system. Chylomicrons then enter the vena cava and circulate in the blood until 
interaction with LPL; after interaction free fatty acids are released and enter in 
peripheral cells. In adipocytes, triglycerides are resynthesized by acyl 
CoA:diacylglycerol acyltransferase (DGAT), but they can be hydrolyzed again by 
adipose TG lipase (ATGL) and hormone sensitive lipase (HSL). Chylomicron 
remnants (CMRs) are internalized into the liver by hepatic LDL receptor (LDLR), 
here triglyceride is packaged with cholesterol and the apoB100 to form VLDL 
particles. In liver, cholesterol packed into VLDL is recycled or synthesized de novo 
by 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) that represent 
rate-limiting step. In plasma LPL hydrolyze triglyceride contained in VLDL with 
resulting release of fatty acids and VLDL remnants (IDL). Thus IDL are hydrolyzed 
by hepatic lipase (HL) with the resulting formation of LDL particles.LDL transports 
cholesterol from the liver to the peripheral tissues in which enter by endocytosis. 
LDL can return to the liver and enter hepatocytes through LDLR. LDRL expression 
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is regulated by proprotein convertase subtilisin/kexin type 9 (PCSK9).PCSK9 
complexes to LDLR, leading to degradation of the receptor. Inthe peripheral cells, 
cholesterol is removed from macrophages after interaction of ApoA-I present on 
HDL particles with ATP-binding cassette A1 (ABCA1) and ABCG1 transporters. 
Unesterified cholesterol incorporated in HDL particles become substrate of 
Lecithin-cholesterol acyltransferase (LCAT) enzyme.Esterified cholesterol can be 
transferred from HDL to apoB-containing particlesby cholesterol ester transfer 
protein (CETP) or, after remodelling by endothelial lipase (LIPG), enters 
hepatocytes via scavenger receptor class B type I (SRB1) [7]. 
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1.2 HDLCHARACTERISTIC  
HDL are a highly heterogeneous lipoprotein family composedby several 
subclasseswith different density, shape and size. They have density 
between 1.063 to 1.21 g/ml, and range in diameter from 70 to130 Å and in 
mass from 200,000 to 400,000 Dalton. On the average,HDL are formed by 
50% lipid and 50% protein. The density ofthe HDL particles is inversely 
related to their size, reflecting therelative contents of low-density non-polar 
core lipid, and highdensitysurface protein. Most part of plasma HDL have 
a globularshape, the central core is composed by non-polar lipids 
(triglycerides andcholesteryl esters) surrounded by a monolayer of polar 
lipids(phospholipids and unesterified cholesterol) and apolipoproteins. 
Current models of HDL describe apolipoprotein molecules disposed like a 
belt wrapping around the lipid core [8-9]. HDL apolipoproteinshave 
amphipathic (detergent-like) properties, determined by regionscontaining 
both polar and non-polar amino acid residues, which areoften located on 
opposite sides of anα-helix [10]. Hydrophobic forces drivethe association 
ofpolar lipids and apolipoproteins in HDL, and the fatty acyl chains and the 
non-polaramino acids side chains are excluded from the aqueous 
environment.The apolipoproteins and the unesterified cholesterol are 
soluble in aqueous environment and can exchange easily 
betweenlipoproteins or with other lipid surfaces (i.e. cell 
membranes).Phospholipids and non-polar lipids have little potential 
forexchange, but through the action of specific lipid transfer proteins, 
theymay be transferred between lipoproteins [8-11]. A minor fraction 
ofplasma HDL has a non-spherical structure, but they consist in discoidal 
bilayer of polar lipids, in which non-polar core is lacked; apolipoproteins 
run from side to sideof the disk, with polar residues facing the aqueous 
phase and nonpolarresidues facing the acyl chains of the lipid bilayer 
[12,13].The protein component of HDL is formed mainly byapoA-I (70%) 
and apoA-II (20%). Two major particle subclasseshave been identified on 
the basis of major apolipoproteins composition: particles containing apoA-I 
only(LpA-I), and particles containing apoA-I and apoA-II (LpA-I: A-II); they 
also carry additional minor proteins and are heterogeneous in size and 
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composition. Recent shotgun proteomic analysis showed that HDL contain 
48 or more proteins, among these apoAIV, apoCs, apoE, lecithin: 
cholesterol acyltransferase (LCAT),cholesteryl ester transfer protein 
(CETP), phospholipid transfer protein (PLTP), paraoxonase (PON), and 
platelet-activating factor acetylhydrolase (PAF-AH) circulate in plasma 
bound to HDL [8-14]. Most of the proteins carried by HDL are not 
apolipoproteins, and represent very minor components of HDL. 
It is possible to classify HDL on the basis of density, charge, shape and 
size.Based on density, two HDL subclasses were identified, called HDL2 
(1.063 to 1.12 g/ml) and HDL3(1.12 to 1.21 g/ml).  
According to charge is possible identify HDL into α- and pre-β-migrating 
particles on the agarose gel and combining charge and size these two 
subclasses can be divided into 12 distinct apoA-I-containing HDL particles, 
referred to as pre-β (pre-β1 and pre- β 2), α (α 1, α 2 and α 3) and pre- α 
(pre- α 1, pre- α 2 and pre- α 3) on the basis of mobility that is slower or 
faster than albumin, respectively, and decreasing size. On the basis 
ofparticle size; five subclasses have been identified and characterized 
HDL3c, 7.2-7.8 nm; HDL3b, 7.8-8.2 nm; HDL3a, 8.2-8.8nm; HDL2a, 8.8.-
9.7 nm; HDL2b, 9.7-12.0 nm [15].  
 
Fig 2.HDL heterogeneity.Schematic representation of HDL subclasses 
according to density, size, charge and apolipoprotein composition (drawings 
not in scale) [8]. 
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1.3 HDL METABOLISM 
The two major apoliporotein in HDL, ApoA-I and A-II, are synthesized 
mainly by the liver and, to a lesser extent, by the small intestine [16]. 
The proteins are secretedas components of triglyceride-rich lipoproteins, 
chylomicronsarising from the intestine and VLDL from the liver. In 
circulation, PLTPpromote the transfer of surface components 
(phospholipids,cholesterol and apolipoproteins) from triglyceride-
richlipoproteins during lipolysis to HLD. The regulatory role of PLTP is 
achieved via its two main functions, phospholipid transfer activity and the 
capability to modulate HDL size and composition in a process called HDL 
conversion [17]. Hepatocytes are able to secrete apoA-I in lipid-free or 
lipid-poor and lipidated forms [18],ApoA-I is secreted as pro-apoA-I and 
converted to a mature form by a metalloprotease in blood plasma [19]. 
There are three potential sources of lipid-poor apoA-I in plasma: it may be 
released as lipid-poor protein after its synthesis in the liver and intestine, it 
may be released from triglyceride-rich lipoproteins that are undergoing 
hydrolysis by lipoprotein lipase, and it may be generated within the plasma 
during the remodeling of mature, spherical HDL particles. Lipid free-apoA-
Iacquires phospholipids and cholesterol peri-cellularlythrough the 
interaction with the ATP binding cassette transporterA1 (ABCA1), to form 
pre-β-HDL, this pathway is dependent on ABCA1 expression. Only 20% of 
total apoA-I produced in liver is intracellularly lipidated, and some of the 
lipidation may not be mediated by ABCA1 [20]. Once in the circulation,pre-
β-HDL are acted on by LCAT, which converts lecithin andcholesterol into 
lysolecithin and cholesteryl esters in a reaction thatuses apoA-I as 
cofactor [21]. The non-polar cholesteryl esters splitthe bilayer and give rise 
to the mature spherical α-HDL (HDL3).The HDL3 interact in the plasma 
with CETP, that exchanges cholesterylesters for triglycerides between 
HDL and triglyceride-rich lipoproteins,generating large cholesteryl ester-
poor and triglyceride-richHDL particles (HDL2) [22]. HDL triglycerides and 
phospholipidsare hydrolyzed by lipolytic enzymes (lipoprotein, hepatic,and 
endothelial lipases), converting spherical α-HDL back to discoidal pre-β-
HDL particles [23, 24]. During this process, someapoA-I dissociate from 
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HDL and are cleared from the circulation,mainly through the kidney [25]. 
Cholesteryl ester-rich HDL3could be also internalized in hepatocytes 
through two different pathways: the first is mediated by SR-BI, located on 
the surface of liver and adrenal cells, which mediates the uptake of 
cholesteryl esters (and unesterified cholesterol) from HDL, without the 
internalization and degradation of the lipoprotein itself [26]. The generated 
cholesteryl ester-depleted, small HDL particles are either remodeled into 
large HDL by incorporation into preexisting HDL, or are cleared through 
the kidney [27,28]. The second might be independent of SR-BI and involve 
the uptake and degradation of the holo-HDL particle by unknown 
receptors. An alternative mRNA splicing variant of SR-BI, named SR-BII, 
can remove HDL from circulation through internalization and co-
localization with transferrin in the endosomal recycling compartment [29], 
this receptor is identical to the β-chain of ATP synthase [30]; however, this 
does not seem to be a major pathway for HDL catabolismin.Rather HDL 
lipids and apoA-Iappear to be catabolized through distinct pathways, 
which requirethe dissociation of the apolipoprotein from its bound lipids. 
HDLlipid clearance occurs by the processes of cellular selective 
uptakethrough SR-BI [26], transfer to other lipoproteins by CETP [22] 
andPLTP [31], and hydrolysis by lipolytic enzymes [23, 24]. Less isknown 
about the catabolism of the HDL protein moiety. Numeroustissue uptake 
studies support the view that the kidney is the principalsite of apoA-I 
degradation, withpresence of apo-A-I on the brush-border and in apical 
granules of proximal tubule epithelial cells [32]. Lipid-poor apoA-I has a 
size, which is lower than thecutoff value of the glomerular barrier, and may 
be readily removedfrom the circulation by glomerular filtration. The filtered 
apolipoproteinis entirely reabsorbed in the proximal convoluted tubule,and 
undetectable in urine [33]. Cubilin,is a multiligand receptorexpressedin the 
apical membrane of various absorptive epithelia including those of the 
kidney, intestine, the yolk sac and placenta[34]. Cubulin is the established 
receptor for endocytosis ofintrinsic factor vitamin B12 , but also binds 
apoA-I with high affinity,and mediates apoA-I endocytosis [35]. The 
proximal tubule of the renal cortex is the major site for the uptake of apoA-
I and most other proteins filtered in the glomeruli. Cubilin is highly 
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expressed in this segment of the nephron, and is probably involved in the 
reabsorption of multiple proteins in the glomerular ultrafiltrate [35].Whether 
the internalizedapoA-I may escape degradation and recycle back to the 
plasma isunknown. However, the fact that all known cubilin ligands 
seeminvolved in lysosome transportation argues against suchtranscytosis 
of apoA-I [33]. Some studies suggest that the kidney isalso capable of 
both filtration and re-absorption of HDL particles;both the molecular shape 
and the charge of the particle influencethe ability of HDL to cross the 
glomerular barrier, with small,discoidal and positively charged HDL 
particles being filtered morereadily than mature HDL [36].Metabolic 
turnover studies in humans have shown that apoA-Ihas a metabolic fate 
separate from apoA-II, and that apoA-I isgenerally catabolized at a faster 
rate than apoA-II; moreover, lipidfreeapoA-I is cleared from plasma at a 
much faster rate than apoAIbound to HDL [37]. It has also been 
established that the fractionalcatabolic rate of apoA-I is the major 
determinant of plasma apoA-Iand HDL levels [38]. Apolipoprotein and lipid 
composition, as wellas particle size, are important determinants of HDL 
catabolism.LpA-I particles are cleared from the circulation at a faster rate 
thanLpA-I: A-II particles, with residence times of 4.4 versus 5.2 days,and 
apoA-I in HDL3 has a substantially faster turnover rate thandoes the 
apoA-I in HDL2 [39]. Triglyceride enrichment of HDLfurther enhances the 
clearance of LpA-I particles, without changesin LpA-I: A-II turnover [40]. 
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1.4 HDL FUNCTION 
1.4.1 REVERSE CHOLESTEROL TRANSPORT 
The most important function of HDL is to promote the removalof 
cholesterol from peripheral cells, including macrophages withinthe arterial 
wall, and shuttle it to the liver for excretion through the bileand feces. This 
process is called reverse cholesterol transport (RCT) and it results in a net 
mass transport of cholesterol from thearterial wall into the bile. This 
pathway is described as anti-atherogenic process by preventing arterial 
cholesterol accumulation,plaque destabilization and development of acute 
cardiovascularevents. Cell cholesterol efflux is the first process in RCT 
and also represents the rate-limiting step. In cell culture experiments 
several distinctpathways have been identified for the exchange of 
unesterified cholesterol between cells and extracellular acceptors [41]. 
Thisexchange can occur by several processes: the simply way is 
characterized by aqueous diffusion according to the direction of 
cholesterolgradient, or through three main distinct, protein-mediated, 
pathways [41]. The protein-mediated pathways consistto an unidirectional 
(cell to acceptor), ATP-dependent pathwaymediated by the ABCA1 
transporter; an ATP-dependent pathwaymediated by the ATP binding 
cassette G1 transporter(ABCG1); an ATP-independent, bidirectional 
pathway mediated bySR-BI. Lipid-free/lipid-poor apolipoproteins, mainly 
apoA-I,represent the principal cholesterol ABCA1acceptors [41]. ABCA1 
and apoA-I interaction promotes cholesterol and phospholipidefflux from 
ABCA1 to apoA-I, with generation of small, discoidal pre-β-HDL. These 
particles can remove further cholesterol from cells through the 
samepathway [43]. All plasma HDL subclasses, including mature α-HDL 
particles and discoidal pre-β-HDL, are efficient cholesterol acceptors via 
the ABCG1 pathway [41, 42]. Both ABCA1 andABCG1 are highly 
expressed in macrophages, especially after cholesterolloading, suggesting 
their critical importance for HDL-mediatedcholesterol efflux. SR-BI 
promotes cell cholesterol efflux to mature α-HDL particles but not to the 
small pre-β-HDL [41, 42]. Thisreceptor mediates a bidirectional flux of 
cholesterol resulting that thelarge cholesteryl esters-rich HDL become 
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cholesterol donorsinstead than acceptors via this pathway. The role of SR-
BI in mediating macrophage RCT in vivo is probably not quantitatively 
important, despite its role to facilitate in vitro cholesterol efflux from 
macrophages to mature HDL has beenshown. [44].Once accumulated into 
HDL, cholesterol is esterified in plasmaby the LCAT enzyme with the 
resulting formation of cholesteryl esters. Thehydrophobic cholesteryl 
esters move to the core of the HDLparticle, and contribute to the 
progressive enlargement of HDL.Through this process also unesterified 
cholesterol is removed from thesurface of HDL, thus helping to maintain a 
free-cholesterol gradientfrom cells to HDL. LCAT has long been 
considerednecessary for efficient RCT, but recent data suggest that even 
if functional LCAT is not present, macrophagecholesterol efflux and RCT 
can occur [45,46]. Large amount of the cholesteryl esters formed by 
theLCAT reaction are transferred to apoB containinglipoproteins in 
exchange for triglycerides through CETP-mediated process (Fig. 3). The 
apoBcontaininglipoproteins are finally catabolized by the liver. In 
humans,CETPpathway represents an important mechanism by which 
HDL-derivedcholesterol is transported back to the liver. Alternatively,HDL-
cholesteryl esters are taken-up by the liver through SR-BI. Additional 
pathway for hepatic cholesteryl ester removal is represented by direct, SR-
BI-dependent uptake of HDL unesterifiedcholesterol by the liver [47]. 
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Fig 3Schematic drawing of Reverse Cholesterol Transport [8] 
 
 
1.4.2 HDL AND ENDOTHELIAL PROTECTION 
Atheroprotection mediated by HDL is not only through their major role in 
RCT, but also through secondary different functions, one of the most 
important is the ability of HDL to maintain endothelial cell homeostasis and 
integrity [50]. 
HDL have potent antioxidant properties, mediated bymolecules carried by 
HDL (PON-1, PAF-AH, and LCAT) or by apoA-I and apoA-II [48], aswell 
as anti-inflammatory and antithrombotic activities [49].  
Usually, the endothelium has been described such as an inert component 
of the vessel wall;but during the past two decades it has become evident 
that the vascular endothelium plays animportant role in maintaining 
vascular homeostasis through the production of alarge number of 
substances that modulate vascular tone, inflammation, and hemostasis. 
Amongthese, nitric oxide (NO) and prostacyclin (PGI2) maintain vascular 
tone and display antithrombotic proprieties. A decrease in their 
bioavailability is a typical characteristic ofendothelial dysfunction, and it 
was demonstrated that HDL are able to increase NO and PGI2 production 
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bydirect and indirect mechanisms [50]. In in vitro studiesonendothelial 
cells, HDL are able to increase endothelialNO synthase (eNOS) protein 
abundance, by modulating both transcriptional and posttranslationallevels 
[51-53], prevent eNOS displacement from caveolae, and stimulateeNOS 
activation. eNOS activation is mediated by the binding of apoA-I to SR-BI; 
however,apoA-I is necessary but not sufficient for eNOS stimulation, since 
lipid-free apoA-I are not able to activate the protein[54]. eNOSenzymatic 
activity is regulated by complex signaltransduction pathways, which 
include the activation of kinases that modify thephosphorylation state of 
the enzyme [55]. Akt kinase activates eNOS through 
directlyphosphorylating at aminoacid position Ser1177; Akt itself is 
phosphorylated and activated by PI3kinase, which in turn is activated by a 
tyrosine kinase. In contrast to eNOS-Ser1177, under certain conditions, 
thephosphorylation of eNOS-Thr495 attenuates enzyme activity. HDL are 
able to stimulate eNOS activation by phosphorylation at Ser1177 via 
Akt,and this is mediated by Src family and PI3 kinases. Enzyme activation 
also requires Srcdependentand PI3 kinase–dependent activation of Erk1/2 
MAP kinases [56]. HDL can also mediate eNOS activation through the 
interaction of sphingosine-1-phosphate (S1P) with itsreceptors [57]. S1P is 
a bioactive phospholipid associated to HDL, in which is specifically bound 
to apolipoprotein M (apoM), which thusrepresents a vasculoprotective 
constituent of HDL [58].  
HDL could enhance PGI2 production incultured endothelial cells through 
several mechanisms. HDL can supply endothelial cellswith arachidonate, 
that is a substrate for PGI2 synthesis [59], or can activate acalcium-
sensitive [60], membrane-bound phospholipase which makes 
endogenousarachidonate available for PGI2 synthesis [61]. In vivo 
experiments support therelevance of HDL in promoting endothelium-
dependent vasodilatation. Inhypercholesterolemic apoE-deficient mice, 
intravenous injections of synthetic HDL (sHDL)restore endothelium-
dependent dilation with a dose-dependent effect [62]. In humans,plasma 
HDL-C concentration is a strong independent predictor of NO-
dependentperipheral vasodilation in healthy individuals, hyperlipidemic, 
diabetic and coronarypatients [63-66]. As already demonstreted in 
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animals, the intravenous infusion of sHDL in subjects 
withhypercholesterolemia or with low HDL-C rapidly restores the altered 
endotheliumdependentperipheral vasodilation through increased NO 
bioavailability [67, 68]. 
Another typical feature of endothelial dysfunction is the increased 
expression of cell adhesion molecules (CAMs) on the surface 
ofendothelial cells [50]. Activatedendothelial cells express different 
adhesion proteins, including vascular cell adhesionmolecule-1 (VCAM-1), 
intercellular adhesion molecule-1 (ICAM-1), platelet endothelial cell 
adhesion molecule-1 (PECAM-1) and E-selectin. It was demonstrated that 
theseadhesion proteins are expressed in arteries in vivo at sites of 
developingatherosclerosis [69], and soluble forms are present at increased 
concentrations in theplasma of human subjects with coronary heart 
disease (CHD) [70]. Adhesion molecules attract circulating monocytes and 
other leukocytes, which after adhesion through integrins to the endothelial 
surface can transmigrate into the intima.In particular E-selectins are 
expressed both in acute and in chronically inflamed endothelium and 
serve as rolling molecules for monocytes, neutrophils, effector T cells, B 
cells, and natural killer cells [71]. E-selectin is synthesized only during 
inflammation and is not constitutively expressed under noninflamed 
conditions. E-selectin is found on endothelial cells after stimulation by 
inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin 
(IL)-1α, or platelet factor 4 (PF4). In E-selectin knockout mice was shown 
a significative reduction in the lesion size in aorta [71]. 
In response to accumulation of cholesterol within the intima of aortas, 
VCAM-1 expression is induced by arterial endothelial cells. In human 
coronary arteries expression of ICAM-1 and VCAM-1 was described. 
Studies on rabbit demonstrated that also an atherogenic diet rapidly 
induces VCAM-1 expression in aortic endothelium. More evidence that 
VCAM-1 expression is regulated by proatherogenic factors are provided 
by study that demonstrated oxLDL-induced upregulation of VCAM-1. 
Lipoproteins containing apoCIIIincrease VCAM-1 and ICAM-1 expression 
in endothelial cells by activating PKCβ and NF-κB pathways. In human 
coronary atherosclerotic plaques, increased levels of VCAM-1 and ICAM-1 
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and increased numbers of plaque intimal macrophages and T cells were 
observed within regions of plaque neovasculazation, but less in the arterial 
luminal endothelium suggesting that VCAM-1– and ICAM-1–dependent 
recruitment of immune cells through intimal neovasculature may 
participate in atherosclerosis [71]. 
Platelet endothelial cell adhesion molecule-1 (PECAM-1), also known as 
CD31, is a member of the immunoglobulin gene superfamily. PECAM-1 is 
mainly expressed at the lateral borders of endothelial cells, but also on the 
surface of hematopoietic and immune cells, including macrophages, 
neutrophils, monocytes, mast cells, natural killer cells, lymphocytes, and 
platelets. PECAM-1 gene polymorphisms and elevated soluble PECAM-1 
levels are associated with severe coronary artery disease. PECAM-1 has 
important signaling properties: acute onset of laminar flow stimulates 
PECAM-1 phosphorylation of intracellular domain, which may promote 
activation of PECAM-1 in atherosclerosis-prone regions of the aortic wall. 
PECAM-1 is a mechanosensitive molecule and is a member of a shear 
stress responsive complex in association with vascular endothelial 
cadherin (VE-cadherin) and vascular endothelial growth factor receptor 2 
(VEGF-R2) [71].  
Integrins are a family of 24 cell-surface receptors composed of 18α and 8β 
subunits that form αβ heterodimers. Integrins are able to mediate the cell-
cell, cell-extracellular matrix, and cell-pathogen contact. Integrins can also 
regulate leukocyte homing, organize the immunologic synapse; participate 
in costimulation, migration, and phagocytosis. Integrins rapidly change the 
conformation of their extracellular domain structure and are able to cluster 
in response to activation; in parallel, ligation of integrins leads to a signal 
cascade from the extracellular domain to the cytoplasm. The main 
integrins that participate in the regulation of leukocyte trafficking are β2 
and α4 integrins. All leukocytes constitutively express LFA-1, a member of 
the β2 subfamily of integrins. LFA-1 binds endothelial molecules that 
belong to the immunoglobulin superfamily, intercellular cell adhesion 
molecule-1, and -2 (ICAMs). α4β1 (VLA-4) integrin is a member of α4 
subfamily and mostly expressed on monocytes and on lymphocytes with 
extralymphoid homing potential and it binds to another member of the 
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immunoglobulin superfamily, VCAM-1, and to the CS-1 peptide of 
fibronectin [71]. 
HDL can down-regulate the CAM expressioninduced by pro-inflammatory 
stimuli in endothelial cells [72, 73], but the mechanisminvolved in HDL-
mediated inhibition of CAM expression has not been fully elucidated.Early 
studies proposed the inhibition of sphingosine kinase activity and of the 
nucleartranslocation of NF-kB by HDL [74]; but more recent studies 
described a role for SR-BI and S1P1 receptor inthe HDL-mediated 
inhibition of CAM expression [75, 76]. HDLcomposition affects HDL anti-
inflammatory activity.The protein componenthas little influence on HDL 
anti-inflammatory activity [77, 78], on the contrary the phospholipid 
composition of HDL, in particular thelength and the degree of unsaturation 
of fatty acid residues, affects this activity [79]. In humans, according toin 
vitro data, plasma HDL-C levels are inversely correlated with plasmalevels 
of soluble CAMs [80]. Subjects with low HDL-C levels also displayan 
increased sensitivity toward inflammatory stimuli as reflected by 
enhancedinflammatory response on endotoxin challenge [81]. It is 
interestingly observed that after the consumption of ameal enriched in 
saturated fat HDL capacity to inhibit CAM expression inendothelial cells 
was reduced, while an opposite effect was observed after a meal enriched 
inpolyunsaturated fat [82].Endothelial cell proliferation and migration are 
crucial processes to bothneovascularization and replacement of damaged 
or senescent endothelial cells.Endothelial repair can occur by migration 
and proliferation of neighboring endothelialcells and through the 
recruitment of circulating endothelial progenitor cells (EPCs), whichcan 
differentiate into endothelial cells and facilitate vascular repair and 
neovascularization[49, 83]. HDL can promote endothelial cell migration 
and proliferation with mechanisms not been clearly defined [49]. HDL also 
reduce the loss ofendothelial cells through inhibition of cell apoptosis. 
Lysosphingolipids associated to HDL areinvolved when the apoptotic 
process is triggered by growth factor deprivation [84],whereas apoA-I is 
involved in the HDL-mediated reduction of cell death induced by cytokines 
[85]. Finally, HDL can modify EPC differentiation and function, thus 
enhancing progenitor -mediatedendothelial repair [86, 87]; but this direct 
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effect of HDL on EPC has been recentlydiscussed, and is likely dependent 
on HDL concentration [88]. 
 
 
 
Table 3Schematic depicting potential basis for HDL-mediated endothelial 
protection in a variety of clinical conditions characterized by endothelial 
dysfunction [50] 
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2 LCAT 
Inherited HDL disorders represent a heterogeneous group of rare 
monogenic diseases and include familial hypo- and hyper-
alphalipoproteinemias. Familial hypoalphalipoproteinemia is characterized 
by a plasma HDL cholesterol (HDL-C) level below the 5th percentile for 
the general population. Known causes of familial 
hypoalphalipoproteinemia are mutations in the APOA1, ABCA1 and LCAT 
genes. Familial hyperalphalipoproteinemia is characterized by a plasma 
HDL-C above the 95th percentile for the general population. The best 
known monogenic cause of familial hyperalphalipoproteinemia is a 
mutation in the CETP gene abolishing CETP activity. Other candidate 
genes include LIPC, LIPG, and SCARBI [89]. 
HDL inherited disorders also represent a unique tool to evaluatehow 
specific HDL subpopulations are involved in the atheroprotective activity 
mediated by HDL.  Due to loss of one of RCT key steps, genetic LCAT 
deficiency permits to evaluate a specific HDL subpopulation and to assess 
the relevance of LCAT enzyme in atherosclerosis.Carriers of two mutant 
LCAT alleles have remarkably low plasma HDL-C, apoA-I, and apoA-II 
levels, associated with multiple alterations in HDL structure and particle 
distribution, with a selective depletion of large particles and predominance 
of small preb-HDL [90, 91]. 
Furthermore the cause of glomerulosclerosis, that is the major cause of 
morbidity and mortality in FLD patients is not understoodand it is 
necessary to be investigated. 
 
2.1 THE LCAT BIOCHEMISTY AND REACTION 
A single copy of the human LCAT gene (∼4.5 kb) is localized on 
chromosome 16 (region 16q22); it contains six exons with ∼1.5 kb of 
coding sequence [92]. The mRNA for LCAT is found almost exclusively in 
the liver, with smaller amounts in the brain and testes. The synthesized 
protein is secreted into the plasma compartment. The mature LCAT is a 
glycoprotein of 416 residues, with a molecular mass of approximately 67 
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kDa, which is more than 20% greater than the predicted protein mass. The 
extra mass is due to both N-linked and O-linked glycosylation [92]. The 3D 
structure of LCAT is not known, but a partial structural model for LCAT has 
been built, based on its homology with lipases [92]. The model proposes 
that LCAT belongs to the α/β-hydrolase fold family. The central domain 
consists of a mixed seven-stranded β-sheets with four α-helices, and loops 
linking the β-strands. The catalytic triad, identified by site-directed 
mutagenesis, includes residues Ser181, Asp345, and His377 [92]. 
The plasma concentration of LCAT (about 5 mg/L) correlates with plasma 
enzyme activity, as assessed with endogenous lipoproteins (cholesterol 
esterification rate) or a standardized exogenous substrate (LCAT activity) 
[92]. The plasma LCAT level varies little in adult humans with gender, age, 
alimentary habits, and smoking. In blood, LCAT preferentially binds to 
HDL; a minority of plasma LCAT circulates bound to apoB-containing 
lipoproteins [92]. 
Three catalytic activities have been demonstrated for the LCAT enzyme: 
acyltransferase activity, phospholipase A2 and lysolecithin acil 
transferase(LAT) activity.The most important are acyltransferase and 
phospholipase activity. First, it cleaves the fatty acid in sn-2 position of 
lecithin and transfersit onto Ser181; then, the fatty acid is transesterified to 
the free3-β hydroxyl group of cholesterol, generating cholesteryl ester 
(CE)[21].  
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Fig. 4.Diagram of LCAT Reaction. Step 1: Cleavage—Phospholipase cleavage 
of fatty acid from sn2 position of phosphatidylcholine (PC) with formation of 
lysophosphatidilcholine (LPC). Step 2: Transesterification— Transfer of fatty acid 
bound to Ser181 of LCAT to the hydroxyl group of cholesterol or other sterol 
acceptor[93]. 
 
By this way, the LCAT reaction accounts for the synthesis ofmost of the 
plasma CE. The lipid substrates for LCAT reside preferentiallyin small, 
discoidal and pre-β-migrating HDL [92]; within these particles LCAT is 
activated by apoA-I and esterifies cholesterol via α-LCAT activity. LCAT 
has also been found on LDL particles but is not as active as on HDLand 
esterifies cholesterol within apoB-containing lipoproteins, via β-LCAT 
activity with apoE as cofactor [92]. The affinity of human LCAT (purified 
 26 
 
from human plasma) for LDL is 2.3 to 4-fold lower than for HDL, with 
apparent Km’s (in nmol CE/hrM) of 0.98 (LDL), 0.19 (HDL2), 2.4 (HDL3) 
and 14 (rHDL) (all x 10 -4) and relative reactivities (app Vmax/app Km) 
compared to rHDL of 6.5% for LDL, 1.3% for HDL2,  16% for HDL3, and 
100% is rHDL [94]. Nonetheless, human LCAT does esterify cholesterol 
on LDL, and mutations that abolish α-LCAT activity (activity on HDL) but 
retain some LCAT activity on apoB-Lipoproteins (β-LCAT activity) produce 
a less severe phenotype than LCAT mutations that have lost activity on 
both HDL and LDL. In fact, a school of thought holds that the difference 
between FLD and FED is that FED patients have LCAT mutations that 
lack α-LCAT activity but still retain some β-LCAT activity. Despite the 
ability of LCAT to esterify cholesterol on apoB-Lipoproteins, a substantial 
portion of CE in human LDL arises from HDL CE’s (made by LCAT) that 
are transferred to LDL via CETP. Either way, LCAT is the primary source 
of cholesteryl esters on apoB-containing lipoproteins [92]. The remainder 
of cholesteryl esters present on lipoproteins are derived from the liver and 
intestine when VLDL and chylomicrons are secreted and are produced by 
one of the two the intracellular enzymes for Acyl-CoA:Cholesterol 
Acyltransferase (ACAT) [95]. 
The third activity of LCAT, the LAT activity, consists in conversion of 
lysophosphatidylcoline to phosphatidylcholine and requires LDL particles. 
Part of the lysolecitihin produced by LCAT reaction may be reacylated in 
the plasma itself presumably on the LDL surface; this reaction is indeed 
stimulated by LDL and does not require apoA-I as cofactor [96]. 
Among exchangeable apolipoproteins, apoA-I is the most efficient 
activator of LCAT and many apolipoprotein coding sequence mutations 
are associated with poor enzyme activation. Three arginine residues in 
apoA-I (R149, R153, and R160) have been suggested to be involved in 
LCAT binding, with multiple hydrogen bonds between the arginine 
guanidinium group and lipid polar groups and phosphatidylcholine ester 
bond may be suggested to become exposed to active center [97]. ApoA-I 
may alternatively influence LCAT activity by activating 
phosphatidylcholine; ApoA-I influences both dynamics and conformation of 
substrate molecule in the boundary layer of phosphatidylcholine molecules 
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adjacent to apolipoprotein molecule at the disc periphery. Data at high 
cholesterol content do not indicate a saturation phenomenon, thus giving 
no evidence for a binding of cholesterol to the enzyme [98].In addition to 
LCAT activation by apoA-I, LCAT is less effectively activated also by 
apoE. apoA-IV and apoC-I. apoE has been reported as the LCAT activor 
on apoB-Lps, which do not have apoA-I but it is possible apoC-I and 
possibly apoA-IV may play a similar role [96]. The requirements for LCAT 
activation by apolipoproteins and peptides are lipid binding and 
amphipathic a-helical structures with a nonpolar face of approximately 100 
degrees, a central region of acidic residues opposite to the nonpolar face, 
and, possibly, a distribution of basic residues at the polar-nonpolar 
interface. ApoA-I residues between 143 and 187 are required for LCAT 
activation. If these residues are altered by site-directed mutagenesis 
apoA-I can no longer activate LCAT [21]. Importantly, LCAT is also 
produced in the brain by primary astrocytes, and esterifies free cholesterol 
on nascent APOE-containing lipoproteins secreted from glia and 
influences cerebral spinal fluid (CSF) APOE- and APOA1 levels. Together 
with APOE and the cholesterol transporter ABCA1, plays a key role in the 
maturation of glial-derived, nascent lipoproteins [99]. So although apoE 
may be not as effective an activator as apoA-I, apoE activation is very 
important in brain lipoprotein metabolism.  
Inhibitors of LCAT include sphingomyelin, hydroperoxides of PC, PC with 
trans-fatty acids and chains of 18 carbons, and apoA-II.Sphingomyelin is a 
strong inhibitor of LCAT activity. Its action is mediated by several 
mechanisms, including a decreased interfacial binding, structural effects 
on apoA-I that may alter apoA-I conformation and charge, and principally 
by a competition with phosphatidylcholine, the acyl donor in the reaction, 
that lead to non-productive binding of sphingomyelin to the active site of 
LCAT [100,101].Hydroperoxides of phosphatidylcholine generated during 
mild oxidation of lipoprotein lipids inhibit LCAT with apparent competitive 
kinetics. Oxidation caused a reduction in plasma phosphatidylcholine 
(PC), an increase in a short-chain polar PC (SCP-PC), and an inhibition of 
the transfer of long-chain acyl groups to cholesterol (LCAT activity) or to 
lyso PC (LAT activity). While oxidation of plasma causes a loss of LCAT's 
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ability to transfer long-chain acyl groups, its ability to transfer short-chain 
acyl groups, from SCP-PC is retained, and even stimulated, suggesting 
that LCAT may have a physiological role in the metabolism of oxidized PC 
in plasma[102]. Trans-fatty acids and chains of 18 carbons also inhibit 
LCAT. The trans unsaturated fatty acids (TUFA) decrease high density 
lipoprotein through their inhibition of LCAT activity, and also alter LCAT's 
positional specificity, inducing the formation of more saturated cholesteryl 
esters, which are more atherogenic. LCAT exhibited significantly lower 
activity with PCs containing 18:1t or 18:2t; the inhibition depended on the 
position occupied by TUFA in the PC, as well as on the paired fatty acid. 
Thus, for human LCAT, 18:1t was more inhibitory when present at sn-2 
position of PC, than at sn-1, when paired with 16:0. In contrast, when 
paired with 20:4, 18:1t was more inhibitory at sn-1 position of PC. Human 
LCAT, which is normally specific for the sn-2 acyl group of PC, exhibited 
an alteration in its positional specificity when 16:0–18:1t PC or 16:1t–20:4 
PC was used as substrate, deriving 26–86% of the total acyl groups for 
cholesterol esterification from the sn-1 position [103]. 
ApoA-II does not activate LCAT and may in fact prevent activation of 
LCAT by apoA-I. The mechanisms involved are probably due to masking 
of sites on apoA-I by apoA-II. Alternatively, apoA-I and apoA-II may 
compete for binding sites on the phosphatidylcholine -cholesterol vesicles 
[104].   Moreover, the transfer of cholesterol from preβHDL to αHDL was 
shown by Castro et al. to be slower in human apoA-I/apoA-II than in apoA-
I transgenic mice; correlating with a more efficient cholesterol efflux in the 
latter [105].Although apoA-II does not activate LCAT, the presence of 
LCAT does enhance fusion of lipidated apoA-I-only (LpA-I) and apoA-II-
only (LpA-II) particles [106].  Kinetic studies show that apoA-II is secreted 
independently of apoA-I particles and the data indicate that LCAT 
esterification of LpA-I and LpA-II particles may enhance formation of LpA-
I:A-II particles [106]. 
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2.2   LCAT, HDL METABOLISM AND REVERSE CHOLESTEROL 
TRANSPORT  
Discoidal pre-β-HDL are the preferred lipoprotein substrate for LCAT. 
These particles are generated through the interaction of lipid-free or lipid-
poor apoA-I with the ABCA1 transporter located on the cell membrane, 
and resulting efflux of cholesterol and phospholipids [107]. The cholesterol 
esters generated by LCAT activity are more hydrophobic than cholesterol 
and they migrate into the hydrophobic core of the lipoprotein, with the 
resulting conversion of small, discoidal preβ-HDL into mature, spherical 
and α-migrating HDL (α-HDL), that represent most of the plasma HDL. α-
HDL can be converted back to preβ-HDL through the CETP and of a 
variety of lipases activities. plasma half-life of preβ-HDL is short, they are 
rapidly cleared through the kidney, while mature α-HDL have a slower 
turnover [108]. LCAT thus plays a central role in intravascular HDL 
metabolism and in the determination of plasma HDL level. 
Beside to its function in HDL metabolism, LCAT has also long been 
believed to play a crucial and critical role in macrophage RCT. It was 
initially proposed by Glomset that the LCAT reaction contributes to cell 
cholesterol efflux, the first and rate-limiting step in RCT, by maintaining the 
cholesterol gradient between the cell membrane and extracellular 
acceptors, thus facilitating cholesterol efflux by passive diffusion [109], or 
through the ATP-binding cassette transporter G1 (ABCG1) transporter 
[110]. Esterification of cholesterol in plasma by LCAT is also necessary for 
cholesterol uptake from the liver, either directly through the scavenger 
receptor SR-BI or indirectly through CETP, and theresulting elimination 
process.However, there are some evidences to doubt about thecritical role 
of LCAT in reverse cholesterol transport. Among these, the evidence that 
LCAT converts pre-β- HDL into α-HDL with the resulting deprivation of the 
best acceptors for cell cholesterol efflux via ABCA1 [111], that represents 
the major player in cholesterol removal from macrophages [112]. 
  
 30 
 
2.3    FAMILIAL LCAT DEFICIENCY AND FISH-EYE DISEASE: 
CLINICAL SIGNS AND SYMPTOMS 
Genetic LCAT deficiency is a rare autosomal recessive disorder with 
anincidence of less than 1 in 200,000, although the frequency is likely to 
be higher because of misdiagnosis or underdiagnosis.LCAT deficiency 
was first described by Norum and Gjone in 1967 in a 33-year-old woman 
living in Norway, who presented with corneal opacities, anemia, 
proteinuria, mild hypoalbuminemia, and hyperlipidemia [113]. The renal 
function was normal, but a kidney biopsy revealed foam cells in the 
glomerular tufts. Plasma cholesterol, triglycerides and phospholipids were 
moderately increased, with most of cholesterol being unesterified; HDL 
could not be detected on agarose gel electrophoresis. Similar clinical and 
biochemical findings were later reported in the proband’s two sisters [114]. 
All three siblings were shown to lack LCAT activity in plasma. About 60 
isolated cases and 70 small nuclear families with partial or complete LCAT 
deficiency were subsequently described. At the best of knowledge, 86 
different molecular defects, spread all along the LCAT gene, have been 
identified in subjects presenting with this rare genetic disorder [115]. Large 
number of LCAT gene mutations has been identified through the 
investigation of single cases, or small families in which a defect in the 
LCAT gene was predicted from the biochemical or clinical presentation. 
Homozygous carriers have a highly variable clinical phenotype; most 
subjects develop corneal opacities and hemolytic anemia; progressive and 
chronic renal insufficiency, often leading to end-stage renal disease, is 
also observed. Heterozygotes reportedly do not have a severe clinical 
phenotype, and LCAT deficiency seems to be transmitted as an autosomal 
recessive disorder. Subjects with loss-of-function mutations in both alleles 
can develop two different LCAT deficiency syndromes, familial LCAT 
deficiency (FLD) and fish-eye disease (FED). All of them are characterized 
by low plasma HDL cholesterol levels; but plasma LDL cholesterol and 
triglyceride levels are widely variable [116]. FLD cases have very little 
amount of esterified cholesterol in plasma and cholesterol accumulates in 
all plasma lipoprotein fractions is basically unesterified. FLD subjects 
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present clinical phenotype with corneal opacity and hemolytic anemia,and 
many of them unpredictably develop renal disease, since the second 
decade of life [117]. FED patients have subnormalplasma esterified to 
unesterified cholesterol ratio and a milder clinicalphenotype [116]. 
Mutations causing FLD can abolish LCAT production, or resultin the 
synthesis of an inactive LCAT enzyme which lacks both α-LCAT andβ-
LCAT activity; mutations causing FED abolish αLCAT activity butβ-LCAT 
activity is retained [116]. The differential diagnosis of FLD andFED in 
carriers of two mutant LCAT alleles requires measurementof the ability of 
plasma to esterify cholesterol incorporated intoendogenous lipoproteins 
(α-LCAT plus β-LCAT activity) and intoa synthetic HDL substrate (α-LCAT 
activity) [118]. It is not possible classify carriers ofone mutant LCAT allele 
as FLD or FED basedon biochemical or clinical criteria [116].Differential 
diagnosissuch as transient expression of LCAT mutants in cultured cells, 
andmeasurement of LCAT concentration and activities (α-LCAT and β-
LCAT activity) in cell media [119] are utilized to classify heterozygous 
subjects. 
 
2.3.1 LIPOPROTEIN, OCULAR AND HEMATOLOGICAL FINDINGS 
LCAT deficiency leads to dramatic changes in laboratory analysis in FLD 
patients: plasma analysis are characterize by an increased percentage of 
unesterified cholesterol (> 75%) and the absence of significantlevels of 
HDL-C (< 10 mg/dL, < 0.26 mmol/L).ApoA-I levels are also typically 
reduced (< 30 mg/dL) Triglyceride levels are also variable and can range 
fromnormal to markedly elevated, depending on the degree of proteinuria 
andrenal dysfunction. Unfortunately, there is no routine clinical 
laboratorymethod for detecting LpX, but depending on the gel system, it 
can sometimesbe observed by lipoprotein electrophoresis and is thought 
to formprimarily in FLD and not FED patients.  
The analysis of HDL by bidimensional electrophoresis,that separate HDL 
for surface charge and size, in LCAT deficient subjects showed a drastic 
redistribution of apoA-I-containing-HDL. Heterozygotes had one extra 
particle in the preβ-1 region (preβ-1×); however, all of their other apoA-I-
containing HDL subpopulations were comparable to controls in 
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electrophoretic mobility and size. ApoA-I distribution in heterozygotes was 
shifted toward the smaller HDL particles: there was a 2-fold increase in 
preβ-1 level, a 23% increase in α-4, and a 45% increase in preα-4 levels 
compared with controls. There were significant decreases in the 
concentrations of all the other HDL particles, whereas the mean 
concentration of α-3, an intermediate-sized particle, was similar to that of 
controls. In homozygotes, the majority of apoA-I was detected in small, 
lipid-poor, disc-shaped HDL particles (preβ-1 and α-4). Despite the low 
plasma concentrations of apoA-I in homozygous subjects, the apoA-I 
concentrations of these particles were comparable to those of controls 
[120].  
 
Fig.5Apolipoprotein A-I (apoA-I)-containing HDL subpopulations of 
representative control, heterozygous, and homozygous LCAT-deficient subjects 
separated by two-dimensional, nondenaturing agarose- PAGE. The asterisk 
represents the endogenous human serum albumin marking the a-mobility front 
[120]. 
 
 
Corneal opacity is the most constant and impressive characteristic in FLD 
and FED patients. Corneal opacity appears since childhood and progress 
over years.Despite the cloudy appearance of the cornea, most FLD and 
FED patients retain relatively normal vision under good lighting conditions. 
Ophthalmological examination of these patients typically shows diffuse 
haziness of the corneal stroma, with more pronounced opacity near the 
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limbus, often arranged in diffuse, grayish, circular bands [116,121]. At first 
analysis it could be identified as general corneal dystrophy and similar 
medical case has been reported in other ipoalfalipoproteinemia such as 
Tangier disease.The diffuse haziness of the corneal stroma is constitute 
by 5-200 nm vacuoles, enhanced by histochemistry and  electron 
microscopy, the membranous deposits in the vacuoles of FLD and FED 
patients probably mostly contain unesterified cholesterol and 
phospholipids, which suggests that LCAT either directly or because of its 
effect on increasing HDL levels normally leads to the removal of 
unesterified cholesterol and phospholipids from the cornea, but this 
process is inadequate in FLD and FED patients [116, 121]. 
 
 
Fig. 6Typical corneal opacity in LCAT deficiency patients [146]. 
 
Most FLD patients have a mild chronic normochromic anemia associated 
with increased reticulocyte.Hematological results showed the changes 
were mainly in erythrocytes with mean corpuscular volume increased by 
7%. Moreover, the erythrocytes were heterogeneous in shape and about 
20% of the cells were represented by Target cells or Knizocytes [122]. 
Erythrocytes presents in subjects with LCAT deficiency have an abnormal 
intramembranedistribution of lipids: total lipid amount of free cholesterol 
and phosphpolipids increased by 27% associated with the completely 
different phospholipid compositions (incrased phosphatidylcholine, and 
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decreased phosphatidylethanolamine); these changes areassociated with 
abnormal properties such as deformability, membrane fluidity [122]. 
Anemia, abnormal shape and the increased mean corpuscular volume of 
this patient’serythrocytes may be related tomembrane instability owing to 
the abnormal distribution of membrane lipids such as cholesterol, 
phosphatidylcholine andphosphatidylethanolamine [122]. 
Renal disease, that represents the main medical complication in FLD 
patients, will be discussed in a separate paragraph.  
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2.4    LCAT AND RENAL DISEASE 
Glomerulosclerosis is the major cause of morbidity and mortality in FLD 
patients and may ultimately lead to renal failure. The cardinal feature is 
progressive glomerular scarring. Early in the disease course, 
glomerulosclerosis is both focal, involving a minority of glomeruli, and 
segmental, affecting a portion of the glomerular globe. With progression, 
more widespread and global glomerulosclerosis develops [123]. 
Proteinuria is the early sign of the disease and usually FLD patients during 
the third and fourth decade of life develop renal failure with symptomatic 
edema and hypertension. The rate of progression of renal disease is 
unpredictable, with some patients rapidly going from mild proteinuria to a 
rapid deterioration in their renal function even in their early 20s. In most 
patients the urine contains protein, erythrocytes and hyaline casts. Most 
urinary protein migrates in the position of albumin on electrophoresis. 
Indices of renal function such as serum creatinine and creatinine 
clearance usually remain normal in the first three decades of life. 
Deterioration of renal function may occur suddenly with progression of 
renal insufficiency and increase of proteinuria. The phenotypic expression 
of FLD is different and depends on diet, abnormal lipoproteins, and 
previous kidney disease [123, 124]  
 
2.4.1 RENAL MANIFESTATION 
Renal biopsy permit a quite accurate diagnosis: light microscopy 
enhances characteristic of focal segmental glomerular sclerosis with 
mesangial expansion, a mild increase in mesangial cellularity, and 
irregular thickening of the glomerular capillary walls [124]. By Oil Red O 
staining, gold standard to stain neutral lipid, is possible detect lipid 
deposits with resulting vacuolization of the glomerular basement 
membrane and a typical “foamy” appearance. Lipid analysis of isolated 
glomeruli shows that the amounts of unesterified cholesterol and 
phospholipids are markedly higher than normal [124]. 
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Fig.7 Renal biopsy from FLD patients analyzed by light microscopy: mesangial 
expansion; basement membrane with “foamy” appearance; foam cells in 
mesangium and in capillary walls[124]. 
 
Immunofluorescence microscopy reveals IgM deposit and bright granular 
staining for C3 is detected in the capillary loops, mesangium, and 
arteriolar walls [125,126]. This lipid deposit could activate complement 
protein and accelerate the injury. 
Electron microscopy also highlights the presence of typical lipid 
electronlucent vacuoles and electron-dense lamellar structures in the 
mesangial matrix, glomerular and tubular basement membrane, and 
Bowman’s capsule [127]. Electrolucent expansion in subendothelium and 
in subephitelial area, intracitoplasmatic lipid droplet in mesangial and 
endothelial cells are also shown. The basement membrane has irregular 
thickening and fused endothelial foot processes. Capillary walls are 
abnormal, showing loss of endothelial cells, irregular thickening of the 
basement membrane, and fused endothelial foot processes. It often has 
the appearance of “moth-eaten holes” in the mesangial and basement 
membrane and can contain lamellar osmiophilic deposits. 
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Fig. 8 Mesangial matrix expansion; mesangial cells nuclei are hypertrophic and 
irregular; lipid droplets in cytoplasmic region (electron microscopy, x 3000 
magnification)[124]. 
 
 
Fig. 9 Basal membranes expansion with irregular bubble aspect (electron 
microscopy, x 7000 magnification)[124]. 
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Sessa et al. [128] observed that patients with FLD showed glomerular 
histological lesions and an immunofluorescent glomerular pattern typical of 
a dense-deposit disease called hypocomplementemic type II 
membranoproliferative glomerulonephritis. 
Besides glomerulopathy, tubular pathology is also been descripted like 
diffuse tubular atrophy with thickening of the tubular basement 
membranes, along with focal interstitial fibrosis and mononuclear cells 
infiltrates [129].  
The pathogenesis of the renal disease in FLD is not completely 
understood. The dramatic changes in lipoprotein profile could be related to 
renal disease, in particular it has been proposed that presence of LpX 
particles and/or possibly large molecular weight LDL (LM-LDL), which 
accumulates in plasma of FLD patients are involved in glomerulosclerosis 
development  [126]. The absence of renal disease in FED is presumably 
prevented by the residual LCAT activity, and the lack of formation of a 
significant amount of LpX. LpX and LM-LDL appear to become trapped in 
capillary loops of the glomerulus and induce endothelial damage and 
vascular injury [126]. However, these abnormal lipoprotein particles are 
not always detected in FLD patients with renal disease [125]. 
 
2.4.2 BIOCHEMISTRY OF LIPOPROTEIN X (LPX) 
Lipoprotein X is an abnormal particle present in the plasma of patients 
LCAT deficiency syndromes or cholestatic liver disease. LpX is principally 
composed by phospholipid and cholesterol, contains a high content of 
phosphatidylcholine (60%) and unesterified cholesterol (30%). LpX is 
associated with the LDL fraction isolated in a density gradient of 1.019-
1.063 g/ml [130]. Under electron microscopy analysis LpX appears as a 
multilamellar vescicle with bi- or multi-layer of phospholipids. The size in 
variable with a diameter from 30 to 70 nm (10-13) Phosphatidylcholine is 
the major phospholipid in LpX and sphingomyelin constitutes the minor 
fraction. It also contains cholesteryl ester (2%), triglyceride (2%), and a 
small amount of protein (6%). The major proteins in LpX are albumin and 
C apolipoprotein (apoC-I, C-II and C-III) [130]. Albumin is trapped in the 
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center of the particle and the apoCs are present on the surface. Some 
apoA-I and apoE may also be associated with LpX particles [130].  
The mechanism of formation of LpX is still poorly understood. It was 
initially believed to be an intestinal lipoprotein, normally catabolised by the 
liver, and accumulating as a result of liver dysfunction. 
In familial LCAT deficiency LpX is likely derived from the surface of 
chylomicron remnants that are not further catabolized due to the lack of 
LCAT activity. An inverse relationship between plasma concentration of 
LpX and LCAT activity has been observed in patients with familial LCAT 
deficiency after blood transfusion, indicating that lack of LCAT activity is a 
prerequisite for LpX formation [131]. LpX-positive sera were identified by 
1% agarose gel electrophoresis followed by staining with Sudan Black, but 
sometimes are hard to detect, especially in frozen samples. LpX did not 
migrate to the anode as opposed to the anodic migration of other plasma 
lipoproteins. 
LpX may also appear in patients with cholestasis from various causes, 
most likely because of the regurgitation of bile salt micelles rich in 
phospholipid into the plasma compartment [130].  
In patients with cholestasis appears dyslipidaemic features include 
hypertriglyceridaemia with persisting apoB48, increased plasma 
phospholipids, decreased LCAT activity, and hypercholesterolaemia. The 
hypercholesterolaemia is mainly due to unesterified cholesterol, which is 
principally transported in the form of LpX. Deficiencies of hepatic lipase, 
lipoprotein lipase and LCAT may also occur in cholestasis [132].  
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2.5    LCAT AND ITS ROLE IN ATHEROSCLEROSIS: HUMAN AND 
IN VITRO STUDIES 
The role of LCAT in the pathogenesisof atherosclerosis is controversial. 
In early cross-sectional studies in patients with angiographically proven 
CHD is reported either decreased[133,134] or increased [133] LCAT 
activity. Moreover, an enhanced cholesterol esterificationrate was strongly 
associated to the presence [135,136] and progression[137] of 
angiographically proven atherosclerotic lesions. Carotid intima-media 
thickness (cIMT) was measured as a surrogatemarker for human 
atherosclerosis [138] and increased LCAT activityand cIMT were reported 
in a relatively small number of patientswith the metabolic syndrome.In 
these patients a highly significant positivecorrelation between LCAT 
activity and cIMT was found [139]. Ina significant large number of subjects 
at high cardiovascular risk, no associationbetween LCAT concentration 
and cIMT was found in men,but raised LCAT concentration was 
associated with increasedcIMT in women [140]. Others two prospective 
studies examinedthe relationship between LCAT and prediction of 
cardiovascular events.In PREVEND [141] and EPIC-Norfolk studies [52] 
were shown that LCAT activity or concentration did not predict 
cardiovascular riskin men. In the latter, a high LCAT concentration was 
associated with a higher risk in women [142]. In these studies different 
measures of LCAT function and clinical end-points were employed, but is 
not possible to draw definiteconclusion.These studies suggest that 
enhanced LCAT activity or concentration may not be beneficial for human 
arteries, or even detrimental in women. However,in a small case-control 
study was shown that decreased LCAT activity in related with ischemic 
heart disease. Theoretically, carriers of LCAT gene mutations should have 
an increased CHD risk, due to low HDL cholesterol level in plasma. 
Analysis of all the cases reported till 1997 indicated that premature CHD is 
not a consistent finding among individuals with LCAT deficiency [143]. In 
particular, CHD was only sporadically reported in FLD cases, on the 
contrary one third of FED cases suffered from premature CHD [143]. 
Vascular structure in individuals with genetic LCAT deficiency was 
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investigated by cIMT measurement.In a first study, 9 carriers of LCAT 
gene mutations, 2 homozygotes and 7 heterozygotes, from large 
Canadian kindred with FLD have been followed for over 25 years, and 
none of these subjects showed any vascular events [144]. In this study, 
unaffected subjects were not included for comparison. The 2 homozygous 
subjects had a cIMT slightly greater than expected from age and gender, 
which did not progress over 4 years. In the heterozygotes were revealed 
cIMT greater than homozygotes and an average cIMT 0.24 mm greater 
than the expected reference value [144]. In the second study 47 
heterozygotes from five Dutch FED families, two with premature CHD 
were involved [145]. Subjects with LCAT deficiencyshowed a modest 
increase in average cIMT compared to unaffected subjects (0.03 mm), 
which became statistically significant after adjustment for a variety of 
confounding factors [145]. Finally, cIMT has been recently investigated in 
40 Italian LCAT deficient subjects (12 homozygotes or compound 
heterozygotes, and 28 heterozygotes) and compared with 80 matched 
control subjects [119]. Average cIMT was 0.07 mm smaller in the carriers 
of LCAT mutations than controls, and the inheritance of a mutated LCAT 
genotype had a remarkable gene-dose dependent effect in reducing cIMT. 
Results from the three cIMT studies in carriers of LCAT gene mutations 
suggest that LCAT deficiency does not remarkably increases preclinical 
atherosclerosis, and could even be protective for human arteries[92].The 
absence of cardiovascular events observed in FLD patients could be 
partially explained by in vitro study in which it was demonstrate that 
functional LCAT is not required for macrophage cholesterol efflux to 
human serum.In this study fasting blood was collected from forty-one 
carriers of LCAT gene mutations, including 14 carriers of two 
mutant LCAT alleles (8 FLD and 6 FED) and 27 heterozygotes. The 
authors demonstrates for the first time that serum from carriers 
of LCAT gene mutations has a greater capacity for cell cholesterol efflux 
through ABCA1 than serum from control subjects, due to the very high 
content of preβ-HDL. In contrast, serum from carriers of 
mutant LCAT alleles is less efficient than serum from control subjects in 
promoting ABCG1- and SR-BI-mediated cell cholesterol efflux. This is 
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probably due to the reduced concentrations of mature HDL. HDL particle 
distribution is drastically altered in LCAT deficient carriers and it is 
characterized by a reduced content of large HDL2 particles and by an 
accumulation of preβ-HDL, which in homozygous carriers represent the 
majority of plasma HDL [146]. The serum content of small preβ-HDL is 
correlated with ABCA1-mediated efflux in control serum, and the 
enrichment of HDL fraction or whole serum with preβ-HDL result in parallel 
increases in ABCA1-dependent cell cholesterol release. Therefore, the 
enhanced ABCA1-mediated cholesterol efflux observed in LCAT deficient 
serum is likely due to the increased serum content of preβ-HDL particles; 
on the contrary sera from carriers of LCAT gene mutations have an 
impaired capacity to efflux cholesterol via ABCG1 and SR-BI. This is 
possibly due both to the reduced content of large, phospholipid-rich 
HDL2 particles, and both to the reduced or absent LCAT activity, which 
contributes to maintain the cholesterol gradient that promotes efflux [147, 
148]. The authors concluded that functional LCAT is not required for 
appropriate macrophage cholesterol depletion and RCT, since cell 
cholesterol can be taken up by discoidal preβ-HDL, which accumulate in 
plasma when LCAT function is compromised and then delivered to 
hepatocytes, possibly through an SR-BI-dependent pathway, for 
subsequent excretion in the bile [146]. 
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2.6     LCAT IN ANIMAL MODELS: STUDIES ON 
ATHEROSCLEROSIS AND RENAL DISEASE 
To better understand the LCAT role in HDL metabolism, in atherosclerosis 
and in renal disease several genetically modified animal models have 
been developed.  
 
2.6.1 LCAT AND ATHEROSCLEROSIS IN HUMAN LCAT TRANSGENIC 
MOUSE MODELS  
The effects of overexpression of human LCAT in mice were investigated 
since 1995 fromdifferent independent groups. Vaisman and colleagues 
generated transgenic mice containing the entire human LCAT gene, 
including 0.851 kb of the 5′ flanking region and 1.134 kb of the 3′ flanking 
region on a C57Bl/6 background [149]. This mice contained 15–120 
copies of the transgene, LCAT mass of 11–109 μg/ml and α-LCAT activity 
of 607–3513 nmol/ml/h were reported. α-LCAT activity in control mice was 
only 32 nmol/ml/h.  A second group generated transgenic mice expressing 
the human LCAT gene (FVB background), under control of either the 
natural or the mouse albumin enhancer and promoter. [150]. This mice 
also express human CETP. α-LCAT activity was 27.6 nmol/ml/h in the 
transgenic mice under control of the natural promoter and 33.7 nmol/ml/h 
under control of the mouse albumin enhancer and promoter, compared 
with 23.0 nmol/ml/h in wild-type mice. Coexpression of human apoAI or 
human apoAI and apoAII leads further increase in LCAT activity. Other 
investigators generated C57Bl/6 mice containing the full-length human 
LCAT gene, including 0.1932 kb of the 5′ flanking region and 0.908 kb of 
the 3′ flanking region [151]. About 30 copies of the transgene were 
integrated into one site. α-LCAT activity was increased from 106 nmol/ml/h 
in controls to 4,431 nmol/ml/h in the transgenic mice. In all three studies, 
human LCAToverexpression increased total cholesterol, basically related 
to an increase in the amount of cholesterol esters transported by HDL. 
The enhanced esterification of free cholesterol in HDL leads accumulation 
of abnormally large HDL particles that were rich in apoE in the circulation 
of these animals [152]. 
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Vaisman LCAT transgenic mice fed for 16 weeks with atherogenic 
dietdeveloped from 1.8-fold to 3.5-fold larger atherosclerotic lesions 
correlated with the number of copies of the human transgene integrated 
[153]. In the Francone mice on the FVB background, a 2.5-fold non-
significant increase in lesion size was observed [154]. However, in the 
presence of human apoAI a 3.4-fold increase in lesion size was observed. 
The Mehlum reported a 3.2-fold increase in lesion size in human LCAT 
transgenic miceafter 17 weeks of atherogenic diet feeding [153]. 
The results obtained from these studies suggest that LCAT 
overexpression did not protect against atherosclerosis.This is probably 
due to the accumulation of dysfunctional large apoeE-rich HDL in the 
plasma of transgenic mice, which were shown to be defective in the 
delivery of cholesterol to the liver through SR-BI pathway[153]. 
In humans, CETP represents an alternative pathway for delivery of HDL 
cholesterol esters to the liver through the transfer of cholesteryl ester to 
apoB-containing lipoproteins. However, in CETP/LCAT double transgenic 
animals, lesions were still 1.9-fold bigger compared with lesions in control 
and single CETP transgenic animals, suggesting that also in the presence 
of CETP, high expression levels of human LCAT is confirmedto be 
proatherogenic in mice[155]. 
 
2.6.2 LCAT AND ATHEROSCLEROSIS IN LCAT KNOCKOUT MOUSE 
MODELS 
On other side, the effects of LCAT lacking in mice were investigated. 
Mouse model for human LCAT deficiency was generated by targeted 
disruption of the LCAT gene in mouse embryonic stem cells [153]. Sakai 
and colleagues generated an LCAT knockout (LCAT KO) mouse in which 
exons 2–5 of LCAT allele were disrupted [156], and another group 
generated a mouse lacking exon 1 [157]. In both cases, α-HDL activity 
was no detectable in the homozygous LCAT knockout mice, whereas 
activity in heterozygous mice was reduced to 30–55% respect control 
mice. In contrast with evidences in human FLD patients, there was no sign 
of corneal opacities or renal insufficiency in homozygous LCAT knockout 
mice at the age of 2–3 months. On chow diet, the plasma concentrations 
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of total cholesterol and HDL cholesterol of the LCAT knockout mice were 
reduced to approximately 24% and 30%, and 7% and 8.4% in the mice 
generated by Sakai and Ng, respectively. Also plasma apoA-I levels were 
reduced to 13% and 19%, respectively. α-HDLlevels and size were 
significantly reduced in the LCAT knockout mice, whereas preβ-HDL was 
increased. In LCAT knockout mice of Sakai et al. fed with atherogenic diet, 
HDL levels in plasma were not detectable. Beside HDL absence,an also 
remarkably lower plasma level of proatherogenic apoB-containing 
lipoproteins was observed. [153, 156]. In addition, some mice 
accumulated LpX and in these mice fed with atherogenic diet, proteinuria 
and glomerulosclerosis characterized by mesangial cell proliferation, 
sclerosis, lipid accumulation, and deposition of electron dense material 
throughout the glomeruli were observed [158]. However, no ocular 
abnormalities were found, even though corneal opacities are associated 
with FLD and FED in humans. 
When LCAT KO mice were crossed with LDL receptor knockout mice, 
CETP transgenic mice, kept on high fat high cholesterol diet (HF/HC) diet, 
or with apoE knockout (apoE KO) mice on normal chow diet, LCAT 
deficiency appeared to be atheroprotective [158]. Similar results were also 
confirmed by Ng and colleagues in experiments on apoE knockout mice 
[157]. In all the cases described, LCAT deficiency was associated with 
significant reduction in the cholesterol content of pro-atherogenic apoB-
containing lipoproteins. It wasalso reported that when LCAT-KO/apoE-KO 
mice were fedwitha high-fat diet without cholate, mice had an elevated 
level of apoB lipoproteins and increased incidence of atherosclerosis 
[159]. It was suggested that the anti-atherogenic effect of LCAT deficiency 
closely correlates with its ability to lower plasma levels of apoB 
lipoproteins, probably also through upregulation of the LDL receptor [158] 
2.6.3 LCAT AND ATHEROSCLEROSIS IN RABBIT MODELS 
Rabbitsexpress CETP and can develop spontaneous atherosclerosis. In 
1996, transgenic New Zealand White rabbits were create by Hoeg and 
colleagues with a 6.2 kb genomic fragment consisting of the entire human 
LCAT gene, including 0.851 kb of the 5′ flanking region and 1.134 kb of 
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the 3′ flanking region [160]. The LCAT transgenic rabbits contained 38–
1,436 copies of the human transgene with an LCAT mass of 1.9–54 μg/ml 
and α-LCAT activity of 219–3,217 nmol/ml/hα-LCAT activity detected on 
the control rabbits was 202 nmol/ml/h. Overexpression of human LCAT in 
the rabbit led to markedly increased of plasma concentrationof large HDL 
particles containing apoE and reduced the concentrations of the apoB-
containing VLDL and LDL particles [160]. Overexpression of LCAT 
reduced also apoAI catabolism, indeed the fractional catabolic rate was 
decreased, whereas apoA-I pool size was increased. In theseanimalsthe 
total surface of aortic lesions in LCAT transgenic rabbits was 7-fold 
smaller than in control rabbits, after 17 weeks of an atherogenic diet. In 
rabbits, overexpression of human LCAT protects against atherosclerosis, 
probably due to the combined effect of the increase in HDL cholesterol 
and the lowering of proatherogenic apoB-containing lipoproteins [161]. 
 
2.6.4 LCAT AND RENAL DISEASE IN MOUSE MODELS 
In 2001, Lambert et al., described renal disease associated with plasma 
Lpx appearance in a subset of LCAT knockout mice on high fat high 
cholesterol diet (HF/HC) [158]. The authors histologically described that 
lesions were characterized by significant reductions in the vascular space, 
expanded mesangial region with increased number of mesangial cells and 
mesangial sclerosis, and increased extracellular matrix with accumulation 
of lipid droplets and macrophages. Filipin and oil red-O staining 
demonstrated the accumulation of free cholesterol and polar lipids in the 
glomeruli. Ultrastructurally, the endothelial cytoplasm and the vascular 
spaces were smaller in LCAT knockout than in controls, and the 
mesangial regions contained an increased amount of extracellular matrix. 
The development of glomerulosclerosis in LCAT knockout mice only while 
on the HF/HC diet, when the plasma levels of apoB-containing lipoproteins 
were increased. Both large LDL and LpX were present in the plasma of 
LCAT knockout mice only on the HF/HC diet. Furthermore, renal lesions 
were only detected in the group of mice that accumulated LpX. These 
findings support the importance of large LDL and LpX in the development 
of renal disease in FLD [158] 
 47 
 
In 2004, Zhu and colleagues generated a LCAT knockout mice crossed 
with sterol regulatory element binding protein (SREBP) 1a transgenic mice 
(S+) that selectively accumulate LpX in the circulation  and  this mouse 
model (S+lcat−/−) develops spontaneous chronic glomerulopathy. The 
light microscopic and ultrastructural features of the S+lcat−/− mouse 
kidneys are remarkably similar to those seen in familial human LCAT 
deficiency [162]. This mouse model and the nephropathy seen in human 
LCAT-deficiency both show light microscopic mesangial matrix expansion, 
glomerular hilar foam cell infiltrates, and lipid deposits in the glomeruli and 
tubulointerstitium. Ultrastructural features are also similar in both, showing 
lamellar osmiophilic deposits in the mesangium, in proximity to the 
glomerular basement membrane, and in the interstitium. The S+lcat−/− 
mice show evidence of mesangial injury, mesangial matrix expansion, and 
glomerulosclerosis progressing from 6 to 10 months of age. This is also 
similar to that seen in human LCAT-deficiency nephropathy, where the 
lesions chronically are associated with progressive mesangial and 
glomerular sclerosis [162].  This mouse model provided inin vivo evidence 
that LpX plays an important role in the spontaneous development of a 
glomerulopathy, very similar to that seen in human LCAT deficiency [162]. 
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2.7   THERAPIES 
Specific treatment for genetic LCAT deficiency is not currently available 
and patients are usually treatedsymptomatically. Patients are candidates 
for corneal and renal transplantation, but thedisease can reoccur in 
transplanted tissue. Probably due the rareness of the disease, therapeutic 
options for FLD are poorlydefined.  
The therapy of LCAT deficiency nephropathy consists mainly to delay the 
evolution of chronic nephropathy on the basis of current available 
therapies such as changes in life style and diet, control hypertension, 
containment of the proteinuria, control of complications. When there is a 
nephrotic syndrome, its conservative management will further problems 
[124]. 
Recently, combined treatment withnicotinic acid and fenofibrate showed 
an amelioration of the lipid profile, a reduction of LpX and areduction of 
proteinuria in one FLD patient. The authors suggest that the LpX levels 
reductionis due to low levels of VLDL and chylomicrons after treatment, 
that represent the phospholipid pool for LpXformation [163]. Therapy with 
angiotensin II receptor blockers and lipid-lowering drugs showed in a case 
report study benefit in blood pressure, lipid abnormalities, proteinuria and 
also kidney function, probably delaying progression to renal failure [164].In 
some severe case kidney transplantation is necessary, but often, after 
renal transplantation the pathology quickly reappearswith lipid may be 
deposited soon after transplantation [165]. 
Early successfulstudies focused to correct the biochemical LCAT deficient 
phenotype through the infusion ofnormal plasma [166] give the basis for 
the development of enzyme replacement therapyas a therapeutic strategy 
for LCAT deficiency. Specific characteristic of LCAT enzyme such as its 
relatively longhalf-life and the fact that LCAT acts in the plasma 
compartment and does not need to bedelivered to a specific tissue or 
cellular compartment support the development of this enzyme 
replacement therapy. Indeed, a recombinant LCAT provedto rapidly 
restore the normal lipoprotein phenotype in LCAT deficient mice, and it 
ispresently under clinical development [167]. 
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AIM  
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The lecithin:cholesterol acyltransferase (LCAT) is the unique enzyme in human 
plasma responsible for the synthesis of cholesterylesters and plays a critical role in 
high density lipoprotein (HDL) metabolism. GeneticLCAT deficiency is a rare 
metabolic disorder characterized by abnormal plasma lipoprotein profile 
characterized by low HDL level, mainly small discoidal pre-β particles, and by 
presence of LpX, an abnormal lipoprotein usually absent in normal plasma and 
detectable only in some pathological cases. 
The impact of LCAT on human atherogenesis is controversial and studies with 
genetically modified animal models in which LCAT was lacked or overexpressed 
leaded to contrasting results; further investigations are still required to assess the 
LCAT role in atherosclerosis [92]. 
Furthermore, renal disease is the major cause of morbidity and mortality in LCAT 
deficiency patients but the cause of kidney failure is poorly understood. The rate of 
progression of renal disease in FLD patients is unpredictable, with some patients 
rapidly going from mild proteinuria to a rapid deterioration in their renal function 
even in their early 20s [124]. 
Aim of my project was to analyze the peculiar characteristic of abnormal 
lipoprotein accumulated in LCAT deficiency subjects and to evaluate LCAT role in 
atherosclerosis and renal disease.  
In Prof. Franceschini’s laboratory at the University of Milan I had access to large 
number of plasma samples from LCAT deficient patients. First aim of my project 
was to assess the role of LCAT in atherosclerosis by evaluation of ability to 
maintain endothelial cell homeostasis mediated by peculiar HDL subclass 
accumulate in LCAT deficient patients. In order to evaluate the capacity of HDL to 
prevent endothelial dysfunction, HDL were isolated from plasma of homozygous 
and heterozygous LCAT deficient subjects and from control subjects, and tested 
on endothelial cells (HUVEC) to prove their ability to promote nitric oxide 
production and to inhibit adhesion molecules expression. 
The project was ended with addition of analysis of expression of genes involved in 
endothelial cell biology homeostasis in animal models that overexpress LCAT 
gene in Dr. Remaley’s laboratory at National Institutes of Health (United States). 
Second aim of my project was to analyze the role of abnormal lipoprotein 
accumulated in LCAT deficiency patients on renal disease. 
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Project was started in Prof. Franceschini’s laboratory in which sera from LCAT 
deficient subjects were tested on renal tubular cells, and inflammation, apoptosis 
and oxidative stress were evaluated. In Dr. Remaley’s laboratory in vivo and in 
vitro studies were performed in order to evaluate the role of LpX in renal cells and 
in glomerulosclerosis development in LCAT knockout mice. Proteinuria was 
evaluated in urine from mice after acute and chronic LpX exposure and kidneys 
from LCAT KO mice injected with LpX were evaluated by confocal microscopy and 
histological analysis. Expression analysis of genes involved in nephrotoxic 
pathway was also performed in order to evaluate which pathway is involved in 
kidney injury mediated by LpX. 
In vitro studies were also performed on mesangial and podocyte cell cultures 
incubated with LpX to clarify which specific cell population is involved. 
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1. LCAT AND ATHEROSCLEROSIS 
1.1 STUDIES ON SUBJECTS WITH GENETIC LCAT DEFICIENCY 
Subjects 
Seventy-seven carriers of LCAT gene mutations, including 15 carriers of two 
mutant LCAT alleles and 62 heterozygotes, and 32 family controls, all belonging to 
Italian LCAT deficient families, volunteered for the study. All subjects were fully 
informed of the modalities and end points of the study and signed an informed 
consent. Fasting blood was collected and plasma prepared by low speed 
centrifugation at 4 °C. Aliquots were immediately frozen and stored at −80 °C until 
assayed. 
 
Measurement of cell adhesion molecules 
Plasma levels of the soluble forms of intracellular adhesion molecule-1 (ICAM-1), 
vascular cell adhesion molecule-1 (VCAM-1) and E-Selectin were measured by 
commercial ELISA kits (R&D Systems). 
These assays employ the quantitative sandwich enzyme immunoassay technique. 
A monoclonal antibody specific for sVCAM1 or sICAM-1 or sE-Selectin has been 
pre-coated onto a microplate. Standards, samples, controls are added and any 
sVCAM1 or sICAM-1 or sE-Selectin presents were bound by the immobilized 
antibody and the enzyme-linked monoclonal antibody specific for sVCAM1 or 
sICAM-1 or sE-Selectin.U nbound materials were washed away. HRP-conjugate 
antibody was added and binds to the captured analyte.  Following a wash to 
remove any unbound substances and/or antibody-enzyme reagent, a substrate 
solution is added to the wells and blue color develops in proportion to the amount 
of protein bound. The color development is stopped turning the color in the wells to 
yellow and the intensity of the color is measured at 450 nm. 
 
Assessment of flow-mediated vasodilation 
Evaluations were performed at fasting, between 8.30 am and 10.30 am to exclude 
circadian variations, abstaining from physical activity and smoking since midnight. 
Ultrasonic scans were performed in a quiet temperature-controlled (22±2°C) room 
by using a B-mode ultrasound device (ESAOTE AU4) equipped with a 7.5–10.0 
MHz linear array transducer, held throughout the scan at the same point of the 
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brachial artery (BA) of the non-dominant arm using a stereotactic device. The 
ultrasonic device was gated to the peak R-wave on ECG and images were 
collected during the end-diastolic phase of each cardiac cycle and recorded on S-
VHS videotapes for off-line measurements. 
Images of the BA were continuously recorded: (i) for 1 min at rest, (ii) during 5 min 
of low-flow obtained by inflating a pneumatic tourniquet placed in the forearm to a 
pressure 30–50 mmHg above the individual systolic blood pressure and (iii) for 3 
min after cuff deflation (i.e. during the reactive hyperemic phase). In each patient, 
the BA diameter (BAD) was measured using dedicated software, which allows the 
automatic and continuous detection of the distance between the media–adventitia 
interfaces of the near and far wall of the vessel. BAD at rest was the average of 
the sixty BAD values obtained throughout the pre-ischemic phase. BAD max was 
the highest BAD value in the hyperemic phase. FMD was calculated as the 
percent change between BAD at rest and BAD max. 
 
HDL purification  
HDL was purified by sequential ultracentrifugation from the plasma of 6 
homozygotes carrying 4 different LCAT mutations, 10 heterozygotes carrying 6 
different LCAT mutations and 10 family controls.  Plasma was isolated from 3 ml of 
blood from each subject. KBr salt was added to plasma to modify density at 1.080 
g/ml and 1.080 g/ml plasma was stratified with a KBr solution at the same density 
and ultracentrifugated overnight. This passage permits first separation of HDL 
from all other lipoproteins that have density smaller than 1.080 g/ml. Then the 
1.080 g/ml plasma was correct with KBr salt to 1.21 g/ml density and stratified with 
1.21 g/ml KBr solution and ultracentrifugated. Thus, HDL were separate from other 
plasmatic protein with greater density and were dialyzed against sterilized saline 
immediately before use.  
HDL protein concentration was determinated by Lowry colorimetric assay and the 
protein content was expressed as mg of protein/ml.  
 
Shpingosine-1-phosphate evaluation 
HDL content of shpingosine-1-phosphate (S1P) was measured by a commercial 
competitive ELISA assay (Echelon Biosciences) and expressed as pmol/mg of 
HDL protein. The S1P coated 96-well plate is blocked to reduce non-specific 
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binding. The S1P standard curve and samples are mixed with the anti-S1P 
antibody before adding to the plate. The anti-S1P antibody binds to the S1P 
coated plate or the S1P in the sample. Following an incubation and plate wash, 
streptavidin- horseradish peroxidase (HRP) is added to the plate and binds to all 
anti-S1P antibodies (labeled with biotin) bound to the plate. After an additional 
incubation and plate wash, Tetramethylbenzidine (TMB) substrate is added to the 
plate and the colorimetric reaction stopped by the addition of 1N sulfuric acid. The 
absorbance at 450 nm is measured and the concentration of S1P in the samples is 
determined by comparison to the standard curve.  
 
1.2 STUDIES ON ENDOTHELIAL CELLS 
Experiments were performed on primary cultures of human umbilical vein 
endothelial cells (HUVEC) purchased from Clonetics (Lonza), in M199 with 0.75% 
BSA, 1% FCS. HDL were used at the protein concentration of 1.0 mg/ml in all 
experiments and were sterilized with 0.22 µm filters before use. 
Cells were growth with complete growth media (M199 with 10% serum, 1% L-
Glutamine, 1% antibiotics, EGF 0.1 ng/ml + FGF 1 ng/ml + ECGF 2 ul/ml) in 12-
well plates until 90% confluence and starved 18 hours before experiment in M199 
with 0.75% BSA, 1% FCS. 
 
VCAM-1 expression 
To evaluate VCAM-1 expression, endothelial cells were incubated overnight with 
HDL, washed with PBS and then stimula
After 8 hours media was collected and cell were lysate with Lysis buffer containing 
20 mM Tris, pH 6.8 
1 mM EDTA, 4% SDS, 20% glycerol,1 mM NaOv, 1 mM NaF, 1 ug/ml leupeptin, 1 
mM benzamidin, 10 ug/ml trypsin inhibitor (soybean), 0.5 mM DTT, 1 mM 
Pefabloc. 
VCAM-1 concentration in conditioned medium was evaluated by a commercial 
matched antibody pairs ELISA kit (BioSource) and normalized by the protein 
concentration of the total cell lysate. This assay employs the quantitative sandwich 
enzyme immunoassay technique. Antibody specific for VCAM-1 has been pre-
coated onto a microplate. Standards and samples are pipetted into the wells and 
any VCAM-1 present is bound by the immobilized antibody. After removing any 
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unbound substances, a biotin-conjugated antibody specific for VCAM-1 is added to 
the wells. After washing, avidin conjugated Horseradish Peroxidase (HRP) is 
added to the wells. Following a wash to remove any unbound avidin-enzyme 
reagent, a substrate solution is added to the wells and color develops in proportion 
to the amount of VCAM-1 bound in the initial step. The color development is 
stopped and the intensity of the color is measured. 
 
eNOS expression 
To evaluate eNOS expression, endothelial cells were incubated overnight with 
HDL (1.0 mg/ml), washed with PBS and lysated with Lysis buffer. Expression of 
eNOS was evaluated by SDS-PAGE and immunoblotting. 
Total protein concentration was assayed by micro-BCA method (ThermoScientific) 
and 25 µg of total protein for each samples were loaded into 8% SDS-
polyacrylamide gel. The ratio charge/mass is constant for the presence of the 
SDS, the separation takes place on the basis of the effects of molecular sieve due 
to the size of the meshes of the gel. The smaller proteins pass through more 
easily, while those of larger size are delayed by frictional forces. Electrophoresis is 
initially performed at 60V so that samples can attributed in stacking gel that, once 
entered into the Running gel the electrophoresis is raised to 80V.  When the 
electrophoresis finished, the protein were transferred into a nitrocellulose 
membrane(Schleicher & Schuell) for 1 hour at 180 mA, in buffer containing 25 mM 
Tris, 192 mM glycin and 15% (v/v) methanol. Membranes were immediately 
saturated with a TBS-T buffer ( 0,018 M Tris, 0,25 M NaCl, pH 7.4, and 0,1% (v/v) 
Tween 20) containing 5% (w/v) nonfat milk, overnight at 4°C. Membranes were 
developed against total eNOS antibody (BD Biosciences) diluted 1:1000 and 
incubated overnight at 4°C, washed 50 minutes in T-TBS solution, incubated with 
a secondary antibody (Dako) conjugated with HRP for 1 hour at 37°C and washed 
again 50 minutes in T-TBS solution at room temperature.  Bands were visualized 
by enhanced chemiluminescence (GE Healthcare Biosciences) and analyzed with 
a GS-690 Imaging Densitometer and Multi-Analyst software (Bio-Rad 
Laboratories). 
The membranes were stripped with a buffer solution containing 0.2 M Glycin, pH 
2.2, SDS 0.1% (w/v) SDS e 1% (v/v) Tween 20 and reprobed with an antibody 
against β-actin (Sigma-Aldrich Chemie) diluted 1:2000. 
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eNOS activation 
To evaluate eNOS activation, endothelial cells were incubated 20 minutes with 
HDL (1.0 mg/ml), washed with PBS and lysated with Lysis buffer.eNOS activation 
by phosphorylation was evaluated by SDS-PAGE and immunoblotting. 
Membranes were developed against phosphorylated eNOS (Ser1177, Cell 
Signalling Technology) diluted 1:1000 overnight 4°C, stripped and reprobed with 
an antibody against total eNOS with method described previously. 
 
Nitric Oxide production 
Nitric oxide (NO) production was evaluated by fluorescence using diacetate 4,5-
diaminofluorescein. Endothelial cells were incubated 30 minutes with HDL (1 
mg/ml), washed with PBS and incubated 2 hours in dark conditions at room 
temperature with buffer containing diacetate 4,5-diaminofluorescein (DAF-2 DA, 
Sigma-Aldrich Chemie). DAF-2DA is a non-fluorescent cell permeable reagent that 
can measure free Nitric Oxide (NO) and nitric oxide synthase (NOS) activity in 
living cells under physiological conditions. Once inside the cell the diacetate 
groups on the DFA-2DA reagent are hydrolyzed by cytosolic esterases thus 
releasing FAD-2 and sequestering the reagent inside the cell. Production of nitric 
oxide converts the non-fluorescent dye, DAF-2, to its fluorescent triaole derivative, 
DAF-2T. Fluorescence intensity was detected (λ excitation= 485 nm, λ emission= 
530 nm) with a Synergy Multi-Mode microplate reader equipped with the GEN5 
software (BioTek).  After detection, cells were lysated with lysis buffer and protein 
concentration was measured with micro-BCA assay. For each sample, 
fluorescence was normalized by the protein concentration of the total cell lysate. 
 
1.3 STUDIES ON ANIMAL MODELS 
Animal 
hLCAT transgenic x hApoA1 transgenic mice, hLCAT transgenic mice, apoE KO 
mice and wild-type mice (background C57/black6) are involved in this study. Mice 
were fed to regular chow diet and were sacrificed at the age of 6.0 months-old. 
The protocol was approved by the National Heart, Lung and Blood Institute Animal 
Care and Use Committee (NIH, Bethesda, MD, United States). 
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Plasma Lipid analysis 
Plasma levels of total cholesterol, free cholesterol, phospholipid and triglyceride 
were determined enzymatically by colorimetric assay kits from Sigma Diagnostics 
and Wako Chemicals. 
Plasma lipoproteins were separated by Fast Protein Liquid Chromatography 
(FPLC) with size exclusion method that separate lipoproteins according to their 
size. Two Superose 6 columns in series (Akta FPLC; GE Healthcare) were utilized 
and 2 mM pH 7.4 Phosphate buffer containing 0.15 M NaCl, 0,03% EDTA and 
0,02% NaN3 was used as mobile phase. 
The chromatographic bed is composed by the gel beads inside the column and 
300 ul of plasma samples were introduced into the injector and carried into the 
column by the flowing solvent. Columns were equilibrated with buffer before 
loading sample. Once in the column, the sample mixture separates as a result of 
different components adhering to or diffusing into the gel. As the solvents is forced 
into the chromatographic bed by the flow rate, the sample separates into various 
zones of sample components and were detected by UV absorption at 280 nm. 
FPLC is performed at 0.5 mL/min constant flow rate for 84 minutes at room 
temperature. Forty-two fractions of 0.5 ml each were collected in 96 wells-plate 
and total cholesterol content was measured in each fraction by Wako enzymatic 
assay. 
 
Gene expression analysis: RNA isolation and Real Time PCR 
Total RNA was extracted from kidneys by Trizol (Invitrogen, Carlsbad, CA) and a 
PureLink Mini Kit (Invitrogen). Kidneys were homogenized in Trizol by Precellys24 
homogenizer and RNA was extracted and purified with a PureLink Mini Kit. RNA 
was quantified by nanodrop spectrophotometer at 260 nm. Absorbance at 230 and 
280 nm was also measured to determine nucleic acid purity. The ratio of 
absorbance at 260 nm and 280 nm is used to assess the purity of RNA; a ratio 
greater than 2.0 is generally accepted as “pure” for RNA. A260:A230 ratio is used 
as a secondary measure of nucleic acid purity and should be greater than 1.7. 
0.5 µg of RNA was retrotranscripted in cDNA by a High-capacity cDNA Reverse 
Transcription Kit (Applied Biosystem). 
The gene expression was evaluated through Real Time PCR Arrays (Qiagen), with 
specific array that analyze the expression of genes involved in cell endothelial 
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biology. SYBR Green-optimized primers are included in 384-well plate and cDNA 
with SYBR Green qPCR Mastermix (Qiagen) formulation are addict to the plate. 
384 different gene-specific products were amplified simultaneously under uniform 
cycling conditions. The cDNA templates were mixed with the appropriate ready-to-
use PCR mastermix, equal volumes (10 µl) was loaded to each well of the same 
plate, and then run the real-time PCR cycling program consisted of an initial 
denaturation of the samples at 95°C for 10 minutes followed by 40 cycles, each 
cycle consisted of a denaturation step at 95°C for 15 seconds and an annealing 
step performed at 60°C for 1 minutes. After 40 repeats samples were heated at 
95°C for 15 seconds, 60°C for other 15 seconds and the ending step of 
denaturation of 15 seconds at 95°C.  The array monitors the expression of 84 
genes related to a disease state or pathway, plus 5 housekeeping genes, also 
included some elements that permit to evaluate the quality of PCR as genomic 
DNA contamination detection, RNA sample quality and general PCR performance. 
Data analysis is based on the ΔΔCT method with normalization of the raw data to 
either housekeeping genes. Relative quantification is used to compare the gene 
expression levels between different groups of mice and results are expressed as 
fold-changes.  
 
1.4 STATISTICAL ANALYSIS 
Results are reported as mean ± SD, unless otherwise stated. Group differences 
were evaluated by one-way ANOVA or unpaired t-test in thehuman studies, and by 
unpaired t-test in animal studies.  
Group differences with a P value <0.05 were considered statistically significant. 
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2.LCAT AND RENAL DISEASE 
2.1 LPX SYNTHESIS AND CHARACTERIZATION 
Synthetic LpX was produced by mixing 30% of unesterified cholesterol (Sigma) 
with 70% of phosphatidylcholine (AvantiLipids) in molar ratio and dried under 
nitrogen for 1 hour, suspended in sterile saline solution, vortexed and sonicated for 
10 minutes. 
To evaluate the correct formation of particles, LpX solution was loaded on agarose 
gel (Sebia gel) and run for 1 hour at 80 V in Barbital Buffer pH 7.4 (Sigma). At the 
end of electrophoresis gel was fixed in water solution containing acetic acid, 
methanol and ethanol for 10 minutes, dried and stained with Sudan Black solution 
(Sigma). Gel was alternatively washed in PBS 1X buffer and stained for one hour 
with Filipin solution and revealed by UV lamp. 
LpX multilamellar structure and size were analyzed by transmission electron 
microscopy (TEM). 3 μL of the LpX preparation was deposited on carbon film-
coated 400 mesh copper grids (Electron Microscopy Sciences) and negatively-
stained with 5 droplets of 1% uranyl acetate solution, the excess of solution on the 
grid was blotted and the grid was dried before TEM observation.  
All images were acquired on JEM 1200EX electron microscope (JEOL USA) 
equipped with an AMT XR-60 digital camera (Advanced Microscopy Techniques 
Corp). Images were acquired at magnifications from 25,000X to 50,000X. 
 
2.2 STUDIES ON PODOCYTE AND MESANGIAL CELLS  
Experiments were performed on mesangial mouse cells and human podocyte 
cells. Mesangial mouse cells were purchased from ATCC, grown with complete 
growth media (DMEM:F12 in ratio 3:1, 14 mM Hepes, 5% FBS) on an 8-well 
chamber slide at a density of 10,000 cells/well. 
Human podocytes were kindly donated by Kopp’s Laboratory and grown at 33°C in 
complete growth medium (RPMI 1640, 10% FBS, 1% ITS, 1% 
Penicillin/Streptomycin/Glutamine solution) and differentiated at 37°C for 15 days 
on an 8-well chamber slide at a density of 30,000 cells/well. 
Cells were starved overnight in media without serum and incubated for 6 hours 
with 0.5 mg/ml with NBD-LpX. One hour before the end of experiment, red 
Lysotracker (Life Technologies) was added to the media at a final concentration of 
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50 nM. Cells were washed with PBS and to each well one drop of DAPI mounting 
solution (Life Technologies) was added.Images were acquired with a point 
scanning confocal microscope LSM 510-UV with three detection channels 
equipped with four lasers: 405 diode, multiline argon, 561 diode, and a 633 diode. 
Images were acquired and processed using ZEN 2009 (Zeiss) software. 
 
2.3 STUDIES ON TUBULAR CELLS 
Experiments were performed on immortalized human tubular cells (HK2 line) 
grown with complete growth media (DMEM:F12 in ratio 3:1, 10% FBS, 1% L-
Glutamine, 1% antibiotics). 
Cells were starved and incubated overnight with media containing 2% serum from 
carriers of LCAT deficiency or from controls and inflammatory parameters and 
apoptosis were evaluated. 
 
Apoptosis analysis 
Apoptosis were evaluated by Annexin V method; Annexin V is an anticoagulant 
protein that preferentially binds negatively charged phospholipids. In the early 
phase of apoptotic process, phospholipid asymmetry is disrupted and 
phosphatidylserine is exposed on the outer leaflet of the cytoplasmic membrane. 
After incubation with serum, cells were washed twice with HEPES-buffered saline 
containing 2 5 mM CaCl2 and 2.5 ug/ml of Annexin V (Biotium) was added for 30 
minutes. 
Annexin V related fluorescence was measured exciting cells at 495 nm and 
emission fluorescence was detected at 519 nm. Data were corrected with 
emission measured in non-treated cells. 
 
Inflammatory parameters 
Real Time PCR for inflammatory parameters was performed using SYBER green 
method (iTaq Universal SYBR Green Supermix -BioRad), primer pairs have been 
designed on different exons to avoid the amplification of DNA contaminations 
eventually present in cDNA preparations and the sequences are reported in table 
1. Briefly, RNA was extracted from cells after incubation with sera according to 
Trizol (Invitrogen) method and 0.8 µg of RNA were retrotranscipted using iScript 
cDNA Synthesis Kit (BioRad). Real-Time PCR consisted of an initial denaturation 
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of the samples at 95°C for 3 min, followed by 40 cycles. Each cycle consisted of a 
denaturation step at 95°C for 10s, a 25-s annealing step at the 60°C. At the end, 
melting curve was evaluted from 60°C to 95°C. 
 
Primers Sequence 
VCAM-1 up CCACAGTAAGGCAGGCTGTAAAAG 
VCAM-1 down CGCTGGAACAGGTCATGGTCAC 
MCP-1 up CAGCCAGATGCAATCAATGCC 
MCP-1 down GGAATCCTGAACCCACTTCT 
GAPDH up CCCTTCATTGACCTCAACTACATG 
GAPDH down TGGGATTTCCATTGATGACAAGC 
Table 1 Sequence of primers utilized in Real Time PCR assay. 
 
Oxidative stress evaluation 
For oxidative stress evaluation, HK2 cells were incubated 1 or 2 hours, 
respectively for ROS and NADPH oxidase evaluation, with medium containing 2% 
serum from LCAT deficient patients or from controls.` 
To evaluate ROS production, cells were incubated 30 minutes with HEPES buffer 
containing 5 µM of carboxy-H2DCFDA (Molecular Probes, Invitrogen), a carboxyl 
derivative of fluorescein, before incubation with media containing sera. Reduced 
and acetylated forms of dichlorofluorescein are non-fluorescent until the acetate 
groups are removed by intracellular esterases and oxidation occurs within the 
cells. Oxidation of the probe can be detected by monitoring fluorescence at 517-
527 nm. 
Cells were lysated and total protein content was measured by microBCA assay 
(ThermoScientific). 
To evaluate NADPH oxidase activity was utilized superoxide-induced lucigenin 
photoemissions based method. 
After 2 hours incubation with 2% serum from carriers of LCAT mutations or 
controls, cells were lysated with 50mM Phosphate buffer pH 7.0 containing 1 ug/ml 
of leupeptin and 1 ug/ml of PMSF (phenylmethanesulfonylfluoride or 
phenylmethylsulfonyl fluoride). 
Lysated cells were suspended in a final volume of 1 ml containing 50mM 
Phosphate buffer, pH 7.0, 1 mM EGTA, 150 mM sucrose, 0.5 mM lucigenin 
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(Sigma). Enzyme reactions were initiated with the addition of 0.1 mM NADPH 
(Sigma) and photoemissions, expressed in terms of relative light units (RLU), were 
measured every min for 5 min using a luminometer. 
 
2.4IN VIVO STUDIES 
Animal 
Wild-type C57BL/6-homozygous LCAT knockout mice backcrossed to strain 
C57BL/6 for eight generations were involved in both the acute study and the 
chronic study. Ten-month-old females mice were fed with regular chow diet. 
Experimental protocol was approved by the National Heart, Lung and Blood 
Institute Animal Care and Use Committee (NIH, Bethesda, MD, United States). 
In the acute study mice received one intravenous injection of dialyzed and 
sterilized 0.5 mg/ml cholesterol LpX, 0.5 mg/ml cholesterol LDL or an equal 
volume of sterile saline solution. Blood was collected at 15 minutes, 3, 6 and 24 
hours after injection and urine was collected 24 hours after injection. 
In the chronic study mice were intravenously injected 3 times per week for one 
month with LpX or saline solution. Urine was collected at the end of each week 
and mice were sacrificed 24 hours after the last injection. 
 
Albumin and creatinine measurement in urine 
Urine albumin is one of the key markers for chronic kidney disease, however to 
compensate for variations in urine concentration, the amount of albumin is 
compared with creatinine concentration. The gold standard to measure the 
excretion of albumin in urine is a 24-hours urine collection; however microalbumin 
to creatinine ratio (UACR) measurement in urine is a more convenient method to 
assess kidney dysfunction and may be less prone to errors due to improper 
collection methods and variations in 24-hours protein excretion compared with a 
random urine specimen. It represents a ratio between two measured substances. 
Both the urine albumin (μg /ml) and the urine creatinine (mg/ml) are measured 
values. Albumin content in urine was measured with commercial indirect 
competitive ELISA (Exocell) that recognizes albumin antigen in samples. Samples 
and rabbit anti-murine albumin antibody were added to plate with mouse albumin-
coated wells. The antibody interacts and binds with albumin immobilized to the 
stationary phase or with that in the fluid phase. A subsequent reaction with anti-
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rabbit IgG-HRP conjugate labels the probe with enzyme. After washing, only the 
antibody-conjugate that bound to the albumin of the stationary phase remains in 
the well, and it is detected using a chromogenic reaction. Color intensity is 
inversely proportional to the logarithm of albumin in the fluid phase.Creatinine 
content was determined by colorimetric assay (Exocell, PA) and is an adaptation 
of the alkaline picrate method [171]. It entails determination of the differential 
absorbance in a sample before and after the addition of acid to correct for color 
generation due to interfering substances [172]. 
 
Kidney collection and confocal and histological analysis 
24 hours after the last injection mice were sacrificed and kidneys collected. 
Kidneys were collected in RNAlater (Invitrogen) for gene expression analysis or in 
10% formalin buffer solution. For histological analysis kidneys were collected in 
OCT solution and frozen at -80°C. After sectioning, kidneys in OCT were 
sectioned with a RM 2050 Microtome (Leica) in 6-10 µm sections, mounted with 
DAPI solution and analyzed with a point scanning confocal microscope LSM 510-
UV with three detection channels equipped with four lasers: 405 diode, multiline 
argon, 561 diode, and a 633 diode. Images were acquired and processed using 
ZEN 2009 (Zeiss) software. 
Kidneys in 10% formalin buffer were embedded in paraffin, cut in 3-µm sections 
and stained with Masson-trichrome (WAKO). In Masson's trichrome staining, three 
dyes are employed to selective stain muscle, collagen fibers, fibrin, and 
erythrocytes. This stain permits evaluation of glomeruli fibrosis enhancing collagen 
deposits in glomeruli. 
 
Gene expression analysis 
mRNA was isolated from kidney with Trizol and PureLink Mini kit as previously 
described. Real Time analysis was performed by SYBER green based method 
with Qiagen Superarray that provides 384-wells plate including primers for 84 
genes involved in nephrotoxic pathway. Data were analyzed with ΔΔCT method 
with normalization of the raw data to either housekeeping genes. Data from mice 
treated with LpX are expressed as fold-changes to control group. 
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2.5 STATISTICAL ANALYSIS 
Results are reported as mean ± SEM, unless otherwise stated. Group differences 
in the acute study were evaluated by one-way ANOVA, with post hoc analysis by 
Tukeys test. Group differences in the chronic study were evaluated by unpaired t-
test or by Mann-Whitney test for non-normal data distribution. Data from in vitro 
studies were analyzed by one-way ANOVA. Group differences with a P value 
<0.05 were considered statistically significant. 
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Results 
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1. LCAT AND ATHEROSCLEROSIS 
1.1 Human studies 
1.1.1 HDL ABILITY TO INHIBIT VCAM-1 EXPRESSION IN ENDOTHELIAL 
CELLS 
The anti-inflammatory capacity of HDL was tested in vitro as their ability to inhibit 
TNF -induced VCAM-1 expression in endothelial cells. On average, HDL isolated 
from controls were able to reduce TNF -induced VCAM-1 expression by 
44.4±4.1% (Figure 1). HDL from LCAT deficient subjects proved to be more 
effective than HDL from controls with a gene-dose dependent effect, since on 
average HDL from heterozygous carriers reduced VCAM-1 expression by 
53.1±7.2% and HDL from homozygous subjects by 65.0±8.6% (Figure 1).
 
 
Figure 1.Inhibition of VCAM-1 expression by HDL. HDL from LCAT deficient 
subjects and controls were tested for their ability to reduce VCAM-1 expression 
induced by TNFα stimulation in endothelial cells. Data are expressed as 
percentage of inhibition of VCAM-1 expression in TNFα-stimulated cells, 
mean±SD. Control n=10 , heterozygous (HEZ) n=10, homozygous (HOZ) n=3. 
Data are statistically analyzed by ANOVA and P trend is 0.0003 
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1.1.2 PLASMA LEVELS OF SOLUBLE CAMS 
Plasma levels of soluble VCAM-1, ICAM-1 and E-Selectin were assessed as 
biomarkers of systemic inflammation. No significant changes of soluble VCAM-1, 
ICAM-1 and E-Selectin plasma levels were detected when values of carriers of 
two, one or zero mutated alleles were tested for trend (Figure 2). Levels of 
sVCAM-1 showed a marked degree of variability in carriers of two mutated LCAT 
alleles and were indeed significantly higher than those of carriers of one mutated 
allele (P=0.017) and controls (P=0.046); this is likely due to the presence of renal 
disease in 9 out of 15 carriers of two mutated alleles (943.5±395.7 ng/ml in 
carriers with renal disease vs 761.1±394.5 ng/ml in disease-free carriers). On the 
contrary, independently from the presence/absence of renal disease, carriers of 
two mutated LCAT alleles did not show a significant increase of sICAM-1 levels, 
while plasma levels of sE-Selectin were even lower than those of carriers of one 
mutated allele (P=0.026). 
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Figure 2. Plasma levels of soluble adhesion molecules 
Levels of soluble VCAM-1 (Panel A), ICAM-1 (Panel B) and E-Selectin (Panel C) 
were measured by ELISA in the plasma of carriers of two or one mutated LCAT 
alleles and controls. Boxes indicate the median and 25-75th percentiles, capped 
bars the 10-90th percentiles, n=15 for two mutated alleles, n=62 for one mutated 
allele and n=32 for controls. P for trend adjusted for age and gender are reported. 
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1.1.3 HDL ABILITY TO MODULATE eNOS EXPRESSION AND ACTIVITY IN 
ENDOTHELIAL CELLS 
The ability of HDL to modulate endothelial production of nitric oxide was tested in 
vitro. HDL from carriers and controls displayed a comparable capacity to increase 
eNOS protein abundance (Figure 3), with a slightly reduced effect of HDL from 
homozygous subjects. 
However, HDL from LCAT deficient subjects proved to be more effective than HDL 
from controls in promoting eNOS activation by phosphorylation with a gene-dose 
dependent effect; indeed, when compared with HDL from controls, eNOS 
activation induced by HDL from homozygous subjects was significantly higher. 
(Figure 4). 
As a consequence, NO production induced by carriers’ HDL was significantly 
higher than that of controls’ HDL (Figure 5). 
 
 
 
Figure 3.eNOS expression by HDL in endothelial cells. Data are expressed as fold 
of increase in HDL-treated vs. untreated cells. Data are mean±SD. Control n=10 , 
heterozygous (HEZ) n=10, homozygous (HOZ) n=3. Data are statistically analyzed 
by ANOVA and P trend is 0.0016 and compared to control group in post hoc test. 
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Figure 4.eNOS activation by HDL in endothelial cells. Data are expressed as fold 
of increase in HDL-treated vs untreated cells. Data are mean±SD. Control n=10 , 
heterozygous (HEZ) n=10, homozygous (HOZ) n=3. 
Data are statistically analyzed by ANOVA and P trend is 0.018 and compared to 
control group in post hoc test. 
 
 
 
Figure 5.Nitric oxide production mediated by HDL in endothelial cells. Data are 
expressed as fold of increase in HDL-treated vs untreated cells. Data are 
mean±SD. Control n=7, heterozygous (HEZ) n=8. Data are statistically analyzed 
by unpaired t-test and P trend is 0.0091 
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Sphingosine-1-Phospate (S1P) is a bioactive sphingolipid carried by HDL that can 
increase the HDL ability to activate eNOS. S1P was measured in HDL isolated 
from plasma of LCAT deficient carriers and from control in order to assess if the 
peculiar ability of HDL formed in LCAT deficiency status to activate eNOS is 
related to S1P content. HDL content of S1P in homozygous LCAT deficiency 
subjects was comparable to that of controls’ HDL (195.0±55.2 pmol/mg protein vs 
221.2±28.5 pmol/mg protein, respectively), while HDL from heterozygous carriers 
showed a slightly higher S1P content (333.8±162.5 pmol/mg protein, P for trend 
0.049). (Fig.6) 
 
 
Figure 6.S1P content in HDL. Data are expressed as mean±SD. Control n=9, 
heterozygous (HEZ) n=9, Homozygous (HOZ) n=3 
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1.1.4 FLOW-MEDIATED VASODILATION 
Arterial function was investigated by measuring flow-mediated vasodilation (FMD). 
FMD measurement in the brachial artery reflects nitric oxide production and 
represents a method for assessing endothelial function [173]. Carriers of LCAT 
mutations displayed FMD values comparable to those of control subjects 
(7.4±2.5% vs 8.3±2.1%, respectively). 
 
Fig 7.Flow-mediated vasodilation in LCAT deficient and control subjects. 
Data are percentage value expressed as mean±SD. LCAT deficient carriers n=7, 
Controls subjects n=21, every 3 controls are matched for gender and age to each 
LCAT deficient carrier.  
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1.2 Animal studies 
1.2.1 PLASMA LIPID PROFILE 
Plasma lipid levels were measured in mice. hApoA1xhLCAT mice showed 
dramatic increase in total cholesterol level compared to mice single transgenic for 
hLCAT or hapoA1, respectively 4.75 and 6 times higher. The observation suggests 
that the interaction between LCAT and apoA-I is not only addictive, but is synergic. 
ApoE KO mice, established model for atherosclerosis, present plasma cholesterol 
levels 8 times higher than control mice but 3 times lower than hApoA1xhLCAT 
transgenic mice. 
 
 TC (mg/dl) TG 
(mg/dl) 
PL  
(mg/dl) 
FC 
(mg/dl) 
CE (mg/dl) CE/TC 
% 
WT 73.9±1.4
 
 
81.5±2.5 170.5±4.7 14.7±0.6 58.2±1.3 78.76 
hAPOA1 160.0±11.64 
**** 
110.3±6.6 274.3±14.8 
** 
42.7±3.2 100.7±6.5 62.94 
hApoA1xhLCAT 966.5±16.8 
**** 
132.5±6.0 
** 
698.7±12.9 
**** 
204.6±4.8 
**** 
805.1±17.6 
**** 
83.29 
hLCAT 216.7±3.3 
**** 
68.8±2.1 211.1±3.8 46.0±1.0 178.3±3.6 
**** 
82.14 
APOE KO 606.2±11.3 
**** 
121.4±3.3 310.1±6.5 
**** 
171.6±6.5 
**** 
453.5±13.5 
**** 
74.81 
 
Figure 8.Table of plasma lipid values in female mice. Value are expressed as 
mean±SEM. WT n=89, hApoA1 n=51, hApoA1xhLCAT n=164, hLCAT n=217, 
ApoE KO n=178. Lipid values from different mouse model were compared to 
normal lipid value in WT mice **p<0.01 ****p<0.0001.  
 
1.2.2 FPLC PROFILE 
Fast protein liquid chromatography permit to separate lipoprotein in plasma 
according to size. It is possible to identify three main regions that correspond to 
VLDL, less retained in column and the first to be eluted, LDL, and HDL, smaller 
and eluted as the last particles. 
It is also possible identify three distinct picks in HDL region, that correspond to 
large, medium and small HDL. 
The analysis of plasma lipoprotein fraction showed that the cholesterol content is 
concentrated in HDL fraction both in hLCAT and hApoA1xhLCAT transgenic mice. 
Compared to wild-type (C57Bl/6N green line) and hApoA1 transgenic mice (blue 
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line) the main HDL pick in hLCAT and hApoA1xhLCATmice is shifted towards 
particles of larger size that are less retained in column.  
 
Figure 9. Cholesterol FPLC profile in mice plasma. Plasma lipoproteins were  
separated by size exclusion chromatography and the cholesterol content was 
measured in each fraction.  
 
1.2.3 GENE EXPRESSION 
Analysis of expression of 84 genes in aorta showed a significant increase in 
expression of genes involved in inflammation and vasoconstriction in hLCAT 
transgenic and in hApoA1xhLCAT transgenic mice respect to wild-type mice. 
Expression of adhesion molecules and integrins is significantly increased as 
shown in figure 10.  
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Figure 10. Expression of genes involved in inflammation in hLCAT and 
hLCATxApoA1 transgenic mice. Results are expressed as fold of increase to value 
of wild –type mice that are represented by black line. Data are mean±SEM, hLCAT 
mice n=3, hApoA1xhLCAT n=3. * p value < 0.05 
Col18a1= Collagen, type XVIII, alpha 1, hLCAT fold-up 3,48 p value 0,032, 
hApoA1xhLCAT fold-up 4,54 p value 0,013 
Fn1=Fibronectin 1, hLCAT fold-up 2,42 p value 0,016, hApoA1xhLCAT fold-up 
3,52 p value 0,006 
Itga5=Integrin alpha 5 (fibronectin receptor alpha), hLCAT fold-up 1,97 p value 
0,020 hApoA1xhLCAT fold-up 3,52 p value 0,012 
Itgav=Integrin alpha V, hLCAT fold-up 1,41 p value 0,016 hApoA1xhLCAT fold-up 
1,68 p value 0,007    
Itgb1= Integrin beta 1 (fibronectin receptor beta), hLCAT fold-up 1,87 p value 
0,027hApoA1xhLCAT fold-up 1,93 p value 0,006    
Itgb3=Integrin beta 3 hLCAT fold-up 3,07 p value 0,016 hApoA1xhLCAT fold-up 
3,35 p value 0,011    
Pecam1=Platelet/endothelial cell adhesion molecule 1 hLCAT fold-up 2,00 p value 
0,020 hApoA1xhLCAT fold-up 1,95 p value 0,008    
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Vcam1=Vascular cell adhesion molecule 1 hLCAT fold-up 2,51 p value 0,024 
hApoA1xhLCAT fold-up 2,96 p value 0,038    
 
Expression of genes involved in vasoconstriction was also significantly enhanced 
in mice with LCAT overexpression (Figure 11). 
 
Fig. 11. Expression of genes involved in vasoconstriction in hLCAT and 
hLCATxapoA1 transgenic mice. Results are expressed as fold of increase to wild-
type mice (black line=1). Data are mean±SEM, hLCAT mice n=3, hApoA1xhLCAT 
n=3.   *p value < 0.05, **p value < 0.001 
Ace= Angiotensin I converting enzyme (peptidyl-dipeptidase A)  hLCAT fold-up 
2,79 p  
value 0,019 hApoA1xhLCAT fold-up 3,20 p value 0,001 
Edn1= Endothelin 1 hLCAT fold-up 2,49 p value 0,018 hApoA1xhLCAT fold-up 
2,24 p value 0,036 
 
The results from up regulation of inflammation genes and the increased 
expression of genes involved in vasoconstriction suggest that there is an alteration 
in aorta endothelial biology when LCAT is overexpressed.
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2.LCAT AND RENAL DISEASE 
2.1 In vitro studies 
2.1.1 CHARACTERIZATION OF LPX 
To evaluate the role of LpX in kidney injury, synthetic LpX were in vitro produced 
and characterized by agarose gel electrophoretic analysis and electron 
microscopy. 
Electrophoretic analysis on agarose gel stained with Sudan Black showed the 
peculiar property of LpX to migrate towards the anode pole in the opposite 
direction from other lipoproteins.  
However, under specific conditions, such as frozen samples, LpX is difficult to 
stain with Sudan Black, that preferentially stained neutral lipid, but it is better 
visualized using Filipin stain as showed in Fig. 12 
Electron microscopy analysis confirmed size and shape of synthetic LpX 
emphasizing the peculiar multilamellar structure (Fig. 13). 
 
 
 
Figure 12. Agarose gel stained with Sudan Black (panel A) and Filipin (panel B). 
Red line represents loading point, 1= synthetic LpX, 2=synthetic LpX freeze-
thawed one time, 3= synthetic LpX freeze-thawed two times, 4=control plasma, 
5=FLD plasma, 6= FLD plasma freeze-thawed one time, 7= FLD plasma freeze-
thawed two times. 
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Figure 13. Electron microscopy image of synthetic LpX. Sample is negatively 
stained with 1% uracil solution and image acquired at 40,000X magnification. 
 
LpX is quickly metabolized in plasma. The detection of fluorescence in plasma 
obtained from LCAT KO mice injected with NBD-labeled LpX showed a maximum 
peak of emission 15 minutes after the injection. After 3 hours post injection the 
emission was reduced to less than the half of the initial peak and after 6 hours the 
signal was completely absent (Fig. 14). 
 
Fig. 14. Time line emission curve of LCAT KO mouse plasma injected with 
fluorescent LpX. Sample was excited at 450 nm and emission was filtered at 535 
nm according to NBD emission spectrum. 
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2.1.2 LPX INTERNALIZATION BY RENAL CELLS 
Glomerular filtration barrier is mainly composed of three layers: endothelial cells 
with fenestrations (70 to 100 nm in diameter), basal membrane and epithelial 
regions constituted by podocytes. Intraglomerular mesangial cells are present in 
the interstitium between endothelial cells of the glomerulus. They also participate 
indirectly in filtration by contracting and reducing the glomerular surface area. 
To assess if LpX affectes the filtration barrier, mesangial and podocyte cells were 
incubated with LpX and ability of cells to internalize the particle was detected by 
confocal microscopy. LpX was internalized both in mesangial and podocyte cells 6 
hours after incubation. Red Lysotracker was added to visualize lysosome 
compartments. In the figures is possible to see LpX and lysosomes co-localization. 
 
 
Fig. 15 Podocyte cells under confocal microscopy. Visualization of LpX by green 
signal (Panel A), lysosomes by red fluorescence (Panel B) and nuclei by blue 
channel (Panel C) and a merge of the images. 
A B 
C merge 
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Fig. 16 Mesangial cells under confocal microscopy. Visualization of LpX by green 
signal (Panel A), lysosomes by red fluorescence (Panel B) and nuclei by blue 
channel (Panel C) and a merge of the images. 
 
  
A B 
C merge 
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2.1.3 INFLAMMATION, OXIDATIVE STRESS AND APOPTOSIS MEDIATED BY 
LCAT DEFICIENCY SERUM IN TUBULAR CELLS. 
Vasoactive compounds, growth factors and cytokines have a role in the 
progression of renal disease promoting cell growth and fibrosis. Analysis of 
VCAM-1 and MCP-1 expression in tubular cells incubated with sera from LCAT 
deficient patients showed increased inflammatory response in cells incubated with 
sera from homozygous subjects as shown in Fig. 17. 
 
 
 
 
Fig. 17. Gene expression of VCAM-1 and MCP-1 in HK-2 cells incubated with 
sera. Data are expressed as mean±SD. * p<0.05, **p<0.01. Control n=3, 
heterozygous (HEZ) n=3, homozygous (HOZ) n=3. 
 
 
Oxidative stress is caused by increased production of reactive oxygen species 
(ROS), nitric oxide, and impaired antioxidant capacity, resulting to necrosis, 
inflammation, apoptosis, and fibrosis of kidney. The exposure of HK-2 to sera from 
homozygotes induced an increase of cellular oxidative stress evaluated as 
NADPH oxidase activity (Fig. 18) and resulting ROS production (Fig. 19). 
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Fig. 18. NADPH oxidase activity in HK-2 cells incubated with sera. Data are 
expressed as mean±SD. Control n=3, heterozygous (HEZ) n=3, homozygous 
(HOZ) n=3. 
 
Fig. 19. ROS production in HK-2 cells incubated with sera. Data are expressed as 
mean±SD. Control n=3, heterozygous (HEZ) n=4, homozygous (HOZ) n=3. Data 
were analyzed by ANOVA and P trend is 0.0085 and compared to control group in 
a post hoc test (Dunnett’s test). 
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Apoptosis is involved in the pathophysiologic changes observed in various renal 
diseases, such as IgA nephropathy, lupus nephritis, and crescentic nephritis [174]. 
Apoptotic process evaluated by Annexin V staining was measured in HK-2 cells 
incubated with sera from homozygous and heterozygous LCAT deficient subjects 
and from controls. The exposure of HK-2 to sera from homozygotes subjects also 
induced a significant activation of the apoptotic cascade. 
 
Fig. 20. Apoptosis in HK-2 cells incubated with sera. Data are expressed as 
mean±SD. Control n=3, heterozygous (HEZ) n=4, homozygous (HOZ) n=3. Data 
were analyzed by ANOVA and P trend is 0.0016 and compared to control group in 
a post hoc test (Dunnett’s test). 
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2.2Animal studies 
2.2.1 ACUTE KIDNEY INJURY 
LCAT KO mice were injected with LpX (0.5 mg/ml cholesterol) or with the same 
cholesterol amount of LDL or saline solution. Microalbumin-to-creatinine ratio in 
urine was significantly increased in LCAT KO mice injected with LpX compared to 
same mutant mice with injected with PBS. However, wild-type mice injected with 
LpX did not show any differences in basal levels of microalbumin-to-creatinine 
ratio in urine, suggesting that LCAT activity in normal mice disassembled LpX 
before arriving in the kidney and causing injury. Although LCAT KO mice injected 
with LDL showed a mild increase in microalbumin-to-creatinine ratio, but a 
significantly lower increase was observed in mice injected with LpX. 
Fig. 21 Microalbumin-to-creatinine ratio in mouse urine. 
Microalbumin-to-creatinine ratio fold increase of 3.36± 0.35 in LCAT KO mice 
(n=6) and 0.97± 0.24 in WT mice (n=3) 24 hours after LpX injection compared to 
the value measured before injection. Microalbumin-to-creatinine ratio fold increase 
of 1.63± 0.56 24 hours after LDL injection and 0.81± 0.1 after PBS injection in 
LCAT KO mice (3 mice for each group). 
Values are expressed as fold of change to baseline level (black line), each mouse 
was normalized on his baseline value measured before the injection. *p<0.05, 
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**p<0.01. Data were analyzed by ANOVA and groups were compared with Tukey 
in post hoc analysis. 
 
 
One week after the injection, microalbumin-to-creatinine ratio decreased but did 
not returne completely to basal levels, indicating that after only one injection, even 
if the injury was transitory, the kidney functionality was not completely restored 
(Fig. 22). 
 
 
Fig. 22 Microalbumin-to-creatinine ratio in mouse urine. 
Microalbumin-to-creatinine ratio in LCAT KO mice injected with LpX measured 1 
day (red bar) and after injection and 7 days (yellow bar) after injection. Values are 
expressed as fold of change to baseline level (black line); each mouse was 
normalized on his baseline value measured before the injection. Microalbumin-to-
creatinine ratio 24 hours after injection fold increase of 3.36± 0.35, 1 week after 
injection fold increase of 1.65± 0.49. *p<0.05 
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2.2.2 CHRONIC KIDNEY INJURY: BIOCHEMICAL AND GENE EXPRESSION 
ANALYSIS  
LCAT KO mice were injected with LpX 3 times a week for 4 weeks and 
microalbumin-to-creatinine ratio was evaluated at the end of each week, 48 hours 
after the last injection. As shown in Fig. 23, mice injected with LpX showed 
constant increase in microalbumin-to-creatinine ratio during all the treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 23.Microalbumin-to-creatinine ratio in LCAT KO mice after LpX or saline 
solution injection. 
Values are expressed as fold of change to baseline level (black line), each mouse 
was normalized on his baseline value measured before starting the experiment (6 
mice for each group). 
Microalbumin-to-creatinine ratio in 1 week injection (48 hours after last injection) 
fold increase of 1.49±0.22 in LpX group and fold increase of 0.83±0.10 in control 
group; in 2 weeks fold increase of 2.03±0.72 in LpX group and fold increase of 
0.69±0.14 in control group; in 3 weeks fold increase of 2.75±0.68 in LpX group and 
fold increase of 0.92±0.17 in control group; in 4 weeks fold increase of 5.35±1.57 
in LpX group and fold increase of 1.38±0.16 in control group. 
 
* 
* 
* 
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After 4 weeks, mice were sacrificed and kidneys collected to evaluate mRNA 
expression of genes involved in the nephrotoxicity pathway. 
Expression of 84 genes was evaluated and the analysis showed that the markers 
of kidney injury (Fig. 24), genes involved in glomerulus cells apoptosis (Fig. 25), in 
inflammation (Fig. 26) and oxidative stress (Fig. 27) were significantly up-regulated 
by chronic presence of LpX in plasma. In the graphs only significant changes in 
gene expression are reported. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 24. Gene expression of markers of kidney injury in LCAT KO mice injected 
with LpX. Results are expressed as fold of increase to LCAT KO mice injected with 
saline solution (red line = 1). * p value < 0.05. 
Gstp1=glutathione S-transferase pi 1 fold increase of 1.32. p value 0.025. 
Oat=ornithine aminotransferase fold increase of 1.49. p value 0.018. 
Odc1=ornithine decarboxylase 1 fold increase of 1.25.p value 0.021. 
Slc22a1=solute carrier family 22 (organic cation transporter), member 1 fold 
increase of 1.40. p value 0.024. 
Slc22a6=solute carrier family 22 (organic anion transporter), member 6 fold 
increase of 1.44 p value 0.011. 
Uchl1=ubiquitin carboxy-terminal hydrolase L1  fold increase of 4.88. p value 0.029 
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Vim=vimentin fold-up 3.01. p value 0.036. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 25. Expression of genes involved in glomerulus cell apoptosis in LCAT KO 
mice injected with LpX. Results are expressed as fold of increase compared to 
LCAT KO mice injected with saline solution (red line = 1). * P value < 0.05. 
Atf3=activating transcription factor 3, fold increase of 1.86. p value 0.035. 
Gadd45a=growth arrest and DNA-damage-inducible, alpha fold increase of 1.60. 
p value 0.015. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 26. Expression of genes involved in kidney inflammation in LCAT KO mice 
injected with LpX. Results are expressed as fold of increase to LCAT KO mice 
injected with saline solution (red line = 1). * p value < 0.05. 
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Cxcl10=chemokine (C-X-C motif) ligand 10 fold increase of 1.81. p value 0.017. 
Cyr61=cysteine-rich angiogenic inducer 61 fold increase of 2.55. p value 0.028. 
Spp1= secreted phosphoprotein 1 fold increase of 2.95. p value 0.017. 
Vcam1=vascular cell adhesion molecule 1 fold increase of 3.08. p value 0.059. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 27. Expression of genes involved in oxidative stress in LCAT KO mice injected 
with LpX. Results are expressed as fold of increase to LCAT KO mice injected with 
saline solution (red line = 1). * p value < 0.05. 
Hmox2=heme oxygenase (decycling) 2, fold increase of 1.45. p value 0.031. 
Nox4= NADPH oxidase 4, fold increase of 1.28. p value 0.034. 
Nqo1=NAD(P)H dehydrogenase, quinone 1, fold increase of 1.89. p value 0.009. 
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2.2.3 CHRONIC KIDNEY INJURY: CONFOCAL AND HISTOLOGICAL ANALYSIS 
Using confocal microscopy it is possible to visualize the emission fluorescence 
produced by NBD, green fluorescent phospholipid used to tag synthetic LpX. 
Auto-fluorescence of kidney slice from control mice was subtracted to emission in 
mice injected with LpX and the net fluorescence was shown in Fig. 28. 
By confocal laser scanning microscopy (Z-stack) is possible to obtain high-
resolution optical images with depth selectivity.  6 µm-section was optical 
sectioned by acquiring in-focus images every 1 µm from selected depths. Images 
were acquired point-by-point and reconstructed with a computer by three-
dimensional reconstruction. 
The Z-stack overview of sample highlighted the presence of bright green spots 
mainly in tubular regions with smaller spots in the glomerulus region. 
 
Fig. 28.40x magnification of kidney slice (6 µm). Nuclei are visualized with DAPI 
and LpX is traced with NBD. 
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The analysis if distinct glomerulus and tubula area permitted a better visualization 
of bright green deposition in kidney confirming that 24 hours after injection LpX 
was mainly accumulated in tubular regions. 
 
 
Fig. 29.63x magnification of tubular (Panel A) and glomerulus region (Panel B). 
Nuclei are visualized with DAPI and LpX is traced with NBD. 
 
Histological analysis emphasizes mainly glomerulosclerosis, with high 
disorganization in glomerular structures. Moreover, glomeruli presented an 
expansion of mesangial matrix and the collapse of capillary tubes as showed in 
Fig 30 (panel A). 
 
Fig. 30.Histological analysis of glomeruli. Slides were stained with Masson 
trichrome staining. Panel A, glomeruli from LCAT KO mice treated with LpX; panel 
B, glomeruli from LCAT KO mice injected with PBS.  
A B 
B A 
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Discussion 
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First objective of the present project was the evaluation of the impact of LCAT 
deficiency or overexpression on endothelial dysfunction. 
Endothelial dysfunction is a peculiar characteristic of atherosclerosis and is 
characterized by transforming vessels of the endothelial surface from non-
adhesive to pro-adhesive surface and is mediated by altered homeostasis balance 
of particles implicated in regulating vascular tone, inflammation and hemostasis 
[50]. Among substances that modulate vascular tone, NO plays a major role. HDL 
are able to stimulate NO production in endothelial cells through eNOS activation. 
eNOS activation requires binding of apoA-I to SR-BI and the resulting activation of 
the PI3 K/Akt signaling pathway that phosphorylates eNOS in multiple sites. The 
enzymatic activity of eNOS is regulated by several post-transcriptional 
mechanisms such as protein–protein interactions, subcellular localization, and 
phosphorylation of serine, threonine, and tyrosine residues. Phosphorylation of 
stimulatory sites and dephosphorylation of inhibitory sites are required for eNOS 
activation and resulting NO production; among sites involved in eNOS activation, 
phosphorylation of Ser1177 is mainly implicated in eNOS activation [175].  
HDL isolated from LCAT deficient carriers showed an elevated ability to activate 
eNOS through Ser1177 phosphorylation,resulting in increased  NO production with 
a gene dose-related effect despite the impaired ability to stimulate eNOS 
expression showed in homozygous carriers of LCAT deficiency. In agreement with 
the in vitro data, carriers of LCAT mutations have flow-mediated vasodilation 
values comparable to control subjects despite the low plasma HDL levels. The 
increased ability of carrier HDL to activate eNOS could be related, at least in part, 
to the increased content of S1P, a bioactive component of HDL which has been 
shown to contribute to the HDL-mediated endothelial protection.  
In contrast to NO anti-atherogenic activity, Endotelin 1 and ACE (angiotensin 
converting enzyme) are implicated in vasoconstriction process. Endotelin1 is a 
potent vasoconstrictor produced by endothelial cells [176] and ACE catalyses the 
conversion of angiotensin I to angiotensin II, which is a strong vasoconstrictor 
involved in the  renin-angiotensin system [177].The evaluation of the expression of 
genes involved in endothelial cell homeostasis when LCAT is overexpressed 
provide additional information to better understand the role of LCAT in 
atherosclerosis. Increased expression of genes involved in vasoconstriction in 
mice that overexpress LCAT supports findings from in vitro experiments that LCAT 
 94 
 
is not required to maintain vascular tone, but on the contrary mice that 
overexpressed LCAT showed up-regulation of genes involved in vasoconstriction 
process such as Ace and Edn1.LCAT is not active in the absence of apoA-I and to 
exclude any doubt regarding LCAT activation, hApoA1xhLCAT transgenic mice 
were utilized in this study. Also in the presence of apoA-I, genes involved in 
vasoconstriction are up-regulated in LCAT transgenic mice.  
Another characteristic of endothelial dysfunction is inflammation.  Leukocyte 
recruitment into sites of inflammation is a tightly regulated process in which 
adhesion molecules and chemokines play crucial roles. Activated endothelium is 
able to increase the production of adhesion molecules; among these, VCAM-1 is 
induced by arterial endothelial cells in response to accumulation of cholesterol 
within the intima and represents a critical feature of atherosclerosis [71]. HDL have 
been shown to down-regulate the cytokine-induced expression of CAMs [72, 73]. 
HDL isolated from LCAT deficient subjects shows a higher capacity to inhibit 
VCAM-1 expression in endothelial cells, with a gene dose-dependent effect; these 
in vitro data were confirmed by in vivo evaluation of plasma levels of soluble 
adhesion molecules.   
Despite the significant reduction in plasma HDL cholesterol levels, sVCAM-1, 
sICAM-1 and sE-selectin levels in plasma of LCAT deficiency subjects are not 
increased, but are comparable to levels measured in control subjects. On the 
contrary, subjects with low plasma HDL cholesterol levels not associated to 
genetic disorders show significant increased levels of soluble adhesion molecules 
[80].  
Inflammation parameters were also evaluated in hLCAT and hApoA1xhLCAT 
transgenic mice, and, once again, LCAT overexpression was related to higher 
expression in aorta genes coding for integrins and cell adhesion molecules. 
hApoA1xhLCAT transgenic mice have total cholesterol levels higher than those of 
apoE knockout mice, a confirmed model of atherosclerosis. However, despite 
tremendous cholesterol levels, hApoA1xhLCAT transgenic mice are protected 
against atherosclerosis compared to apoE knockout mice (en face aorta analysis 
and expression of genes related to endothelial cell homeostasis, data not shown). 
These data would explain that despite the increased endothelial dysfunction 
respect wild-type mice, the comparison with mouse model with similar total 
cholesterol levels did not show increase in atherosclerosis.  
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This combined analysis suggests that overexpression of LCAT does not improve 
endothelial protection not does it enhance atherosclerosis. 
The in vitro and in vivo data described in the present thesis suggest that the 
specific HDL subpopulations which accumulate in LCAT deficiency [120], mainly 
small discoidal pre-β HDL, are more effective in maintaining endothelial 
homeostasis than control HDL. On the contrary, the large HDL formed when  
LCAT is overexpressed are less efficient than control HDL in regulating vascular 
tone and inflammation, probably also due to the lack of CETP in mice. 
Data shown in this work together with previous study on efflux cholesterol capacity 
[146] and carotid intima-media thickness evaluation in LCAT deficient subjects 
[119] demonstrate that carriers of LCAT mutations are not exposed to higher 
cardiovascular risk compared to subjects with HDL levels in normal range. 
Moreover, this finding is also in agreement with recent data on general population 
in which LCAT mass was positively related to IMT and cardiovascular risk [140, 
142]. 
The second objective of the present study was to evaluate the role of abnormal 
lipoproteins present in plasma of carriers of LCAT deficiency in renal injury. Renal 
failure is the first cause of morbility and mortality in LCAT deficient carriers, but the 
cause of kidney injury is poorly understood. A possible implication of LpX, an 
abnormal lipoprotein detected in plasma of LCAT deficient homozygous carriers 
[126], has been suggested in earlier reports [127, 130]. Urine albumin is one of the 
key markers for chronic kidney disease. The gold standard to measure urine 
albumin excretion is a 24-h urine collection; however microalbumin to creatinine 
ratio (UACR) measurement in urine is a more convenient method to assess renal 
dysfunction and may be less prone to errors due to improper collection methods 
and variations in 24-h protein excretion compared with a random urine specimen 
[178]. Microalbumin to creatinine ratio was measured in mice urine before and 24 
h after single LpX injection; LCAT KO mice showed significant increase in UACR 
compared with baseline levels, whereas no change was observed in wild-type 
mice, suggesting that the LCAT knockout condition is crucial to develop LpX-
mediated kidney injury. When LDL with the same amount of cholesterol was 
injected in mice that lacked LCAT, no significant changes were observed 
compared with baseline levels. This is probably due to the different forms of 
cholesterol contained in the two particles; LpX contains only unesterified 
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cholesterol, whereas in LDL cholesterol is mainly esterified. Previously, it was 
demonstrated that ratio free cholesterol tocholesterol ester is specifically increased 
in damaged kidney [179].  Microalbumin to creatinine ratio measured 48 h after 
multiple LpX injection was consistently increased during the 4 weeks, suggesting 
that the chronic exposure to LpX increases kidney damage. 
The analysis of genes involved in nephrotoxic pathway highlighted the 
inflammatory status of kidneys of LCAT knockout mice after 4 weeks of chronic 
LpX exposure. Vasoactive compounds, growth factors and cytokines have a role in 
the progression of renal disease promoting cell growth and fibrosis; up-regulation 
of genes associated with adhesion molecule VCAM-1 and cytokines such as 
CXCL10 and Spp1 was found in LCAT knockout injected with LpX for 1 month. 
Expression of VCAM-1 and MCP-1, one of the key chemokines that regulate 
migration and infiltration of monocytes/macrophage [180], was also enhanced in 
tubular cells exposed to sera from LCAT-deficient patients.These findings underlie 
inflammatory kidneys status, resulting in associated fibrosis [181].  
Oxidative stress in another feature of kidney disease; it mediates a large number 
of renal impairments, from acute renal failure, rhabdomyolysis, obstructive 
nephropathy, hyperlipidemia, and glomerular damage to chronic renal failure and 
hemodialysis [182].  
Among genes involved in oxidative stress, Nox4 has been implicated in the basal 
production of ROS in the kidney. Under pathologic conditions such as diabetic 
nephropathy and chronic kidney disease, up-regulation of Nox4 was described as 
crucial in renal oxidative stress and kidney injury [183]. Hmox2 is also implicated in 
ROS generation and it was up-regulated after LpX injection. Data from in vitro 
studies on tubular cells showed overexpression of NADPH after incubation with 
LCAT deficiency serum. The direct measurement of ROS production in tubular 
cells after exposure to sera from carriers of LCAT mutations confirmed the higher 
oxidative stress related to abnormal lipoprotein profile in LCAT deficiency 
compared with normal lipoprotein profile in control subjects. 
Pathogenesis of renal disease in LCAT deficient patients is not clear and it is 
difficult to establish whether it is related to tubular sclerosis or glomerulosclerosis. 
Evidences of both tubular and glomerular disease are evident in the experiments 
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performed. Confocal analysis highlighted LpX deposition mainly in tubular cells, 
but histological Masson trichrome stain showed evidence of severe 
glomerulosclerosis in mice injected with LpX. Histological analysis showed a 
disorganization in glomerulus structure with capillary tube collapse and mesangial 
matrix expansion.In glomerulus, both mesangial and podocyte cells are able to 
internalize LpX. Once internalized in mesangial cells, LpX could promote 
apoptosis as demonstrated by overexpression of Atf3 and Gadd45α genes after 
LpX chronic exposure. Atf3 is an immediate early gene and promotes glomerular 
mesangial cell apoptosis, which is considered a contributor to the initiation of 
nephritis. Increase of Atf3 expression has a promoting role in glomerular cells 
apoptosis with a mechanism that directly involves up-regulation of Gadd45α gene 
expression [184].  
Once internalized in podocytes, LpX promotes up-regulation of UCH-L1 
expression. It was previously demonstrated that UCH-L1 expression in podocytes 
is significantly higher in different kidney diseases such as acute proliferative 
glomerulonephritis, lupus nephritis,membranous glomerulonephritis and IgA 
nephropathy than that in focal segmental glomerulosclerosis [185]. On the other 
hand, LpX has toxic activity also in tubular cells. Significant increase in tubular 
cells apoptosis was observed after incubation with serum from carriers of two 
mutant LCAT alleles.  
Furthermore, up-regulation of genes related to tubular toxicity, such as Nqo1 and 
Cyr61, was observed in mice treated for 1 month with LpX. It was previously 
demonstrated that Cyr61 plays a functional role in the pathogenesis of renal 
tubulointerstitial fibrosis [186]. 
In summary, in this work was shown that LpX is involved in renal disease 
pathogenesis with a non-specific pathway that allows mesangial, podocyte and 
tubular cell injury. The lack of LCAT enzyme is clearly crucial for kidney injury 
mediated by LpX; indeed in wild-type mice LpX did not show any signs of kidney 
injury. Future studies should investigate the reversibility of glomerulosclerosis 
under LCAT replacement therapy or with other pharmacological treatments.  
In conclusion, the experiments described in the present work helped in clarifying 
the role of the LCAT enzyme, a key player in lipid metabolism, in HDL-mediated 
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endothelial protection and in the kidney injury observed in LCAT deficiency. The 
work was made possible by the availability of a large series of American and 
Italian families carrying LCAT gene mutations collected and characterized in the 
last decade. 
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